Biohazard2020/2021-COVID-19 novel coronavirus (2019-nCoV))病毒: 新型冠状病毒 2019-nCoV

Moorestown, New Jersey, United States

7322321334

7322321334

  • biotecMAX
  • BioHazard2021
    • biohazard2021-4
    • BioHazard2020-3
    • BioHazard2020-2
    • BioHazard2020-1
    • BioHazard2020-0
  • BiotecMAX2021
    • 2021-2
    • 2021-1
  • biotecMAX2020
    • 2020-6
    • 2020-5
    • 2020-4
    • 2020-3
    • 2020-2
    • 2020-1
  • BiotecHOPE
    • biotecHOPE
    • biotecHEART
  • biotecNOVA
    • biotecNOVA 2
    • BiotecNOVA 1
  • biotecAlpha
    • portfolio
    • BiotecDATA
  • BiotechVortex
    • biotechVORTEX 2
    • biotechVORTEX 1
  • BiotecMAX2019
    • 2019-12
    • 2019-11
    • 2019-10
    • 2019-9
    • 2019-8
    • 2019-7
    • 2019-4
    • 2019-3
  • BiotecWARS
    • biotechSTORM/BiotecWARS
  • seeking biotech alpha
    • blogs
    • about
  • More
    • biotecMAX
    • BioHazard2021
      • biohazard2021-4
      • BioHazard2020-3
      • BioHazard2020-2
      • BioHazard2020-1
      • BioHazard2020-0
    • BiotecMAX2021
      • 2021-2
      • 2021-1
    • biotecMAX2020
      • 2020-6
      • 2020-5
      • 2020-4
      • 2020-3
      • 2020-2
      • 2020-1
    • BiotecHOPE
      • biotecHOPE
      • biotecHEART
    • biotecNOVA
      • biotecNOVA 2
      • BiotecNOVA 1
    • biotecAlpha
      • portfolio
      • BiotecDATA
    • BiotechVortex
      • biotechVORTEX 2
      • biotechVORTEX 1
    • BiotecMAX2019
      • 2019-12
      • 2019-11
      • 2019-10
      • 2019-9
      • 2019-8
      • 2019-7
      • 2019-4
      • 2019-3
    • BiotecWARS
      • biotechSTORM/BiotecWARS
    • seeking biotech alpha
      • blogs
      • about
  • biotecMAX
  • BioHazard2021
  • BiotecMAX2021
  • biotecMAX2020
  • BiotecHOPE
  • biotecNOVA
  • biotecAlpha
  • BiotechVortex
  • BiotecMAX2019
  • BiotecWARS
  • seeking biotech alpha
seeking biotech alpha

seeking biotech alpha is biotecMAX 生物技术最大 4/20/2021 the heart of biotech

seeking biotech alpha is biotecMAX 生物技术最大 4/20/2021 the heart of biotechseeking biotech alpha is biotecMAX 生物技术最大 4/20/2021 the heart of biotech

BiotechVortex™

Vortexes are powerful and transformational centers of energy

 The BiotechVortex™ section of this site was created when I started seeing an increase in partnerships, mergers, and co-operative agreements, in both the biotech and medtech sectors. Here we will highlight these partnerships/agreements/mergers, even when no  specific products are identified.  

BiotechVORTEX - First Group Page

BiotechVortex™ - Second Group Page

BiotechVortex™

Novadiscovery inks new clinical simulation collaboration with Takeda

Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance

Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance

 

Novadiscovery announces new clinical simulation collaboration with Takeda

Fri March 26, 2021 8:00 AM|GlobeNewswire


Novadiscovery announces new clinical simulation collaboration with Takeda

Lyon, France – 26 March, 2021 Novadiscovery (“NOVA”

 

About NOVA

NOVA is a leading health tech company using in silico clinical trials to predict drug efficacy and optimize clinical trial development. The Company aims to improve R&D productivity and maximize patient outcomes by predicting the clinical benefit of a potential new drug candidate through computer simulation, ahead of human trials.

NOVA’s innovative approach leverages disease modeling and simulation expertise accumulated over the past decade and combines mathematical models of diseases and potential new treatments with virtual patients in its integrated clinical trial simulation platform, Jinkō®.

NOVA is headquartered in Lyon, France and has a team of around 30 scientists, engineers & clinicians who work at the interface of biology, pharmacology, mathematics & computer science.

For more information, please visit https://www.novadiscovery.com

 

Novadiscovery inks new clinical simulation collaboration with Takeda

Mar. 26, 2021 8:12 AM ET

Takeda Pharmaceutical Company Limited (TAK)

By: Aakash Babu, SA News Editor

  • Takeda Pharmaceutical Company (NYSE:TAK) and leading health tech company Novadiscovery have entered into a new collaboration aimed at incorporating clinical simulation technology on virtual patients into Takeda France’s access strategy.
  • https://seekingalpha.com/news/3676726-novadiscovery-inks-new-clinical-simulation-collaboration-with-takeda
  • https://seekingalpha.com/symbol/TAK


The JINKO platform is NOVA’s unified in silico clinical trial simulation platform

Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance

Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance

Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance

 

Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance

  • EVOTEC LEVERAGES ITS PROPRIETARY SMALL MOLECULE RNA TARGETING PLATFORM AGAINST MULTIPLE RNA TARGETS ACROSS TAKEDA’S KEY INDICATIONS
  • EVOTEC RECEIVES RESEARCH FUNDING AND IS ELIGIBLE FOR SUCCESS-BASED MILESTONES AND TIERED ROYALTIES

Hamburg, Germany, 22 March 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has entered into a multi-RNA target alliance with Takeda Pharmaceutical Company Limited (“Takeda”) with the goal to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches.

Evotec and Takeda will jointly identify and develop small molecules targeting a range of RNA targets aligned with Takeda’s research and development areas. The collaboration will leverage Evotec’s extensive RNA targeting platform to optimally identify promising RNA sequences to target with small molecule ligands that can be developed into potentially first-in-class therapeutics.

Under the terms of the agreement, Evotec will receive significant research funding and will be eligible to receive discovery, pre-clinical, clinical, commercial and sales milestone payments of up to US$ 160 m per programme. Additionally, Evotec is entitled to tiered royalties on net sales of any products resulting from the collaboration. 

 

About Evotec’s RNA platform

The structure-based recognition of RNA tertiary structures by RNA-targeted small molecules (“rSM”) provides an alternative to sequence-based approaches, such as antisense oligonucleotides (“ASOs”). rSM approaches enable novel therapeutic potential by allowing to target highly conserved parts of RNA, creating pathways in cases where the encoded protein cannot be targeted conventionally, and unlocking the largely unexplored field of non-coding RNAs, which can also be disease drivers. 

Evotec’s proprietary RNA targeting platform is specifically designed to

  1. identify RNA tertiary structural elements where rSM are able to bind with sufficient selectivity and affinity,
  2. discover and develop suitable rSM binders that potentially deliver orally available drugs, and
  3. identify and deliver proof-of-target engagement for disease-relevant RNA structures, allowing biologically active rSM binders. 

Evotec’s cutting-edge RNA small molecule platform builds on the well-established drug discovery routes within Evotec and combines them with novel, highly innovative technologies such as third generation sequencing, sequencing-based structure elucidation of RNA molecules, which constitute a first-class expertise in this area.


 For more information, visit www.takeda.com. 


 

Evotec, Takeda form strategic RNA targeting alliance

Mar. 22, 2021 6:43 AM ET

Evotec SE (EVOTF)

By: Jignesh Mehta, SA News Editor

  • Evotec SE (OTCPK:EVOTF) has entered into a multi-RNA target alliance with Takeda Pharmaceutical Company (NYSE:TAK) to discover and develop RNA targeting small molecule therapeutics for desirable targets that are difficult to address via conventional approaches.

https://seekingalpha.com/news/3674655-evotec-takeda-inks-strategic-rna-targeting-alliance


https://seekingalpha.com/symbol/EVOTF


https://seekingalpha.com/symbol/TAK


EVT Innovate develops drug discovery programmes and assets, both internally or through academic collaborations. Evotec seeks to partner these into collaborations in return for upfront payments, ongoing research payments and significant financial upside through milestones and royaltie

Enlivex enters Allocetra research collaboration with Yale Cancer Center

Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance

Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Ger

 03/22/2021

Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra™ in Combination with Immune Checkpoint Inhibitors

Collaboration aims to evaluate the potential of Allocetra™ in combination with immune-checkpoint inhibitors in solid cancers that do not respond to stand-alone checkpoint inhibitor therapies.

Nes Ziona, Israel, March 22, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, together with Yale Cancer Center, a National Cancer Institute-designated comprehensive cancer center, today announced a research collaboration for the assessment of the potential of Allocetra™ to enhance the activity of checkpoint inhibitors in solid tumors.  Allocetra™ is a macrophage-reprogramming immunotherapy product candidate currently in clinical development by Enlivex, as, among other things, a potential therapy in combination with approved immune checkpoint inhibitors for hard-to-treat solid tumors. 

Under the strategic collaboration, the parties intend to develop and execute pre-clinical programs to investigate the potential synergies between Allocetra™ and commercially-approved checkpoint inhibitor therapies for select solid cancers. 

 

The Principal Investigator for this collaboration is Dr. Vish Muthusamy, PhD, Director of the Yale Center for Precision Cancer Modeling.  Dr. Muthusamy is a cancer biologist with expertise in preclinical investigation of candidate cancer therapies. His center has developed in vivo tumor models to investigate pharmacological evaluation of drugs. Recently, Dr. Muthusamy worked in close collaboration several academic investigators and pharmaceutical companies to develop cancer therapeutics that are in various stages of clinical development. The collaboration's scientific advisor is Dr. Marcus W. Bosenberg, MD, PhD, Co-Leader of the Genomics, Genetics and Epigenetics Program at Yale Cancer Center. On behalf of the Yale team, Dr. Bosenberg said "At Yale we have been interested in trying to understand the process of macrophage reprogramming for some time, and we are excited about studying the effects of Allocetra™ in potentially recruiting anti-tumor macrophages in the tumor environment and characterize the effects."

Dror Mevorach, M.D., Chief Medical Officer of Enlivex, commented, "We are excited to collaborate with the distinguished research and clinical teams at Yale. Allocetra™ may have a rebalancing effect on the typically immunosuppressive tumor microenvironment, potentially by facilitating the conversion of pro-tumor macrophage populations to anti-tumor populations. Together, we plan to investigate the potential of AllocetraTM to synergistically combine with commercially available checkpoint inhibitors for the treatment of solid tumors."  

Oren Hershkovitz, Ph.D., CEO of Enlivex, stated, "We believe the researchers and clinicians at Yale are world-class and ideal partners as we work to realize Allocetra's potential. We are pleased to formulate a strategic collaboration with Yale for the development of Allocetra™ as a potentially key component of combination therapies for solid tumors."

Allocetra™ is currently in clinical development for acute life-threatening immune-mediated diseases, such as sepsis and COVID-19. Enlivex recently reported positive top-line results in 21 patients from Phase Ib and Phase II investigator-initiated trials in COVID-19 patients in severe/critical condition. The Company has also previously reported positive results from a Phase Ib investigator-initiated trial in 10 sepsis patients and plans to initiate a controlled, randomized, Phase IIb study in sepsis during the first quarter of 2021.


About Yale Cancer Center 

Yale Cancer Center (YCC) is one of only 51 National Cancer Institute-designated comprehensive cancer centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital Care Centers in Connecticut and Rhode Island. Comprehensive cancer centers play a vital role in the advancement of the NCI's goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.


ABOUT ALLOCETRATM

Enlivex is developing AllocetraTM as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as "unmet medical needs," as a stand-alone therapy or in combination with leading therapeutic agents. 


ABOUT ENLIVEX 

Enlivex is a clinical stage immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. 


For more information, visit http://www.enlivex.com.

 

Enlivex enters Allocetra research collaboration with Yale Cancer Center

Mar. 22, 2021 8:35 AM ET

Enlivex Therapeutics Ltd. (ENLV)

By: Aakash Babu, SA News Editor

  • Enlivex Therapeutics (NASDAQ:ENLV) announces a research collaboration with Yale Cancer Center for the assessment of the potential of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors.

https://seekingalpha.com/news/3674731-enlivex-enters-allocetra-research-collaboration-with-yale-cancer-center


https://www.yalecancercenter.org/


 

Allocetra™ Macrophage reprogramming

https://enlivex.com/allocetra/



https://seekingalpha.com/symbol/ENLV



Allocetra™ Macrophage reprogramming

Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Ger

Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Ger

Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Ger

 Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate XL092 and Avelumab in Various Forms of Locally Advanced or Metastatic Urothelial Carcinoma

PDF Version

– New expansion cohorts to be added to ongoing STELLAR-001 trial following dose-escalation phase –

ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 18, 2021-- Exelixis, Inc. (Nasdaq:EXEL) today announced a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer for the ongoing phase 1b dose escalation study STELLAR-001 (previously called “XL092-001”), adding three new cohorts that will evaluate the safety and tolerability of XL092, Exelixis’ novel next generation tyrosine kinase inhibitor (TKI), in combination with avelumab (BAVENCIO®), an anti-PD-L1 immune checkpoint inhibitor (ICI), in patients with locally advanced or metastatic urothelial carcinoma (UC). Avelumab is being co-developed and co-commercialized by Merck KGaA, Darmstadt, Germany and Pfizer. Exelixis is sponsoring the STELLAR-001 clinical trial, and Merck KGaA, Darmstadt, Germany and Pfizer will provide avelumab for use in the trial.

 

“We are pleased to collaborate with Merck KGaA, Darmstadt, Germany and Pfizer to study the potential of XL092 in combination with avelumab as part of the broad development program evaluating our novel next generation tyrosine kinase inhibitor across a wide variety of cancers,” said Gisela Schwab, M.D., President, Product Development and Medical Affairs and Chief Medical Officer, Exelixis. “Although several therapies are now available to treat bladder cancers, the prognosis for patients with advanced disease remains poor and more options are needed. Evaluating how XL092 may positively impact care when paired with immunotherapy is central to our goal of improving therapeutic outcomes for patients with this and other difficult-to-treat cancers.”

Based on the dose-escalation results, the trial has the potential to enroll up to three expansion cohorts evaluating XL092 in combination with avelumab in metastatic UC, including as maintenance therapy, in patients who have progressed following treatment with an ICI, and in patients previously treated with platinum-containing chemotherapy.

XL092 is an investigational, next-generation oral TKI that targets VEGF receptors, MET, AXL, MER and other kinases implicated in the growth and spread of cancer. Preclinical findings presented at the 32nd EORTC-NCI-AACR Symposium in October 2020 showed that XL092 in combination with an ICI was more efficacious than either XL092 or anti-PD1 alone. Single-agent avelumab is the only ICI approved in the U.S. for maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-based chemotherapy.

More information about this trial is available at ClinicalTrials.gov.

 

About XL092

XL092 is a next-generation oral TKI that targets VEGF receptors, MET, AXL, MER and other kinases implicated in cancer’s growth and spread. In designing XL092, Exelixis sought to build upon the experience and target profile of cabozantinib, the company’s flagship medicine, while improving key characteristics, including clinical half-life. XL092 is the first internally discovered Exelixis compound to enter the clinic following the company’s reinitiation of drug discovery activities.


 View source version on businesswire.com: https://www.businesswire.com/news/home/20210318005146/en/ 


 

Pfizer, Merck KGaA and Exelixis to collaborate in bladder cancer trial

Mar. 18, 2021 8:32 AM ET

Exelixis, Inc. (EXEL)

By: Dulan Lokuwithana, SA News Editor5 Comments

  • Exelixis (NASDAQ:EXEL) announced a collaboration with Pfizer (NYSE:PFE) and Merck KGaA (OTCPK:MKGAF) in an ongoing phase 1b dose-escalation study, STELLAR-001 for XL092, the company’s oral tyrosine kinase inhibitor targeting cancer growth and spread.  

https://seekingalpha.com/news/3673995-pfizer-merck-kgaa-and-exelixis-collaborate-in-bladder-cancer-trial


https://seekingalpha.com/symbol/EXEL


 Exelixis Inc (NASDAQ: EXEL) has announced a clinical trial collaboration and supply agreement with Germany's Merck KGaA and Pfizer Inc (NYSE: PFE) for the ongoing Phase 1b dose-escalation study STELLAR-001. 


https://seekingalpha.com/symbol/MKGAF


https://seekingalpha.com/symbol/PFE


Exelixis' XL092 To Be Tested In Combination With Bavencio In Urothelial Carcinoma Vandana Singh , Benzinga Staff Writer March 18, 2021 9:10am

Gilead and Novo Nordisk Expand NASH Clinical Collaboration

Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Ger

illumina inks deal with Geneseeq for in-vitro diagnostic NGS kit in china

 

March 18, 2021

Gilead and Novo Nordisk Expand NASH Clinical Collaboration

– Triple Combination Regimen to be Investigated in New Phase 2b Study in NASH Patients with Cirrhosis –

FOSTER CITY, Calif. & BAGSVÆRD, Denmark--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Novo Nordisk A/S (Nasdaq Copenhagen: NOVO B) today announced that the companies have expanded their clinical collaboration in non-alcoholic steatohepatitis (NASH).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210318005315/en/


 The companies will conduct a Phase 2b double-blind, placebo-controlled study to investigate the safety and efficacy of Novo Nordisk’s semaglutide, a GLP-1 receptor agonist, and a fixed-dose combination of Gilead’s investigational FXR agonist cilofexor and investigational ACC inhibitor firsocostat, alone and in combination in people with compensated cirrhosis (F4) due to NASH. The four-arm study in approximately 440 patients will evaluate the treatments’ impact on liver fibrosis improvement and NASH resolution and will begin recruitment in the second half of 2021. 


 For more information, visit novonordisk.com, 


 

Gilead and Novo Nordisk expand collaboration in NASH therapeutics

Mar. 18, 2021 7:02 AM ET

Gilead Sciences, Inc. (GILD)

By: Dulan Lokuwithana, SA News Editor4 Comments

  • Gilead Sciences (NASDAQ:GILD) and Novo Nordisk (NYSE:NVO) have announced an expansion of their clinical collaboration in non-alcoholic steatohepatitis (“NASH”).

https://seekingalpha.com/news/3673924-gilead-and-novo-nordisk-expands-collaboration-in-nash-therapeutics


https://seekingalpha.com/symbol/GILD


https://seekingalpha.com/symbol/NVO


Gilead Sciences and Novo Nordisk expand NASH clinical collaboration Triple combination regimen to be investigated in new phase 2b study in NASH patients with cirrhosis Foster City, California, US and Bagsværd, Denmark, 18 March 2021 – Gilead Sciences, Inc. and Novo Nordisk A/S today announced that the companies have expanded their clinical collaboration in non-alcoholic steatohepatitis (NASH).

illumina inks deal with Geneseeq for in-vitro diagnostic NGS kit in china

Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Ger

illumina inks deal with Geneseeq for in-vitro diagnostic NGS kit in china

 

Geneseeq Inks Deal with Illumina to Develop and Commercialize Comprehensive Cancer In-vitro Diagnostic NGS Kit in China

Tue March 16, 2021 10:00 AM|PR Newswire|About: ILMN

TORONTO, March 16, 2021 /PRNewswire/ - Next-generation sequencing (NGS)-based precision oncology provider Geneseeq Technology Inc. ("Geneseeq"), will collaborate with Illumina, Inc. (ILMN) ("Illumina") to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer, using Illumina's NextSeq™ 550Dx sequencing platform. The companies will work together to promote the use and application of world leading Next-Generation-Sequencing technology to enhance standards-of-care for Chinese patients.

Geneseeq's comprehensive genomic profiling panel, GeneseeqPrime®, analyzes genomic alterations in 425 cancer-related genes and assesses key biomarkers, such as tumor mutation burden (TMB) and microsatellite instability (MSI).  This pan-cancer panel screens for actionable clinical next steps to therapy by providing valuable insight into key oncogenic genes and drug resistance mechanisms. In 2020, Geneseeq's TMB Testing Kit in non-small cell lung cancer (NSCLC) became the first comprehensive NGS panel entered into the Breakthrough Medical Devices Program of Chinese National Medical Products Administration (NMPA). This is the second time that the two companies joined forces to accelerate clinical availability in precision cancer care. In 2018, the two companies collaborated on the NMPA approval of the IVD kit, Essencare®(EGFR/ALK/ROS1/BRAF/KRAS/HER2 mutation testing kit, Reversible terminator sequencing) for NSCLC. 


 For more information, please visit their website  


 To learn more, visit www.illumina.com  

 

View original ontent:

http://www.prnewswire.com/news-releases/geneseeq-inks-deal-with-illumina-to-develop-and-commercialize-comprehensive-cancer-in-vitro-diagnostic-ngs-kit-in-china-301247592.html 

SOURCE Geneseeq Technology Inc. 


illumina inks deal with Geneseeq for in-vitro diagnostic NGS kit in china

Mar. 16, 2021 11:49 AM ET

Illumina, Inc. (ILMN)

By: Aakash Babu, SA News Editor

  • Illumina (ILMN +0.5%) signs deal with precision oncology provider Geneseeq Technology to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer, using Illumina's NextSeq 550Dx sequencing platform in China.
  • https://seekingalpha.com/news/3673204-illumina-inks-deal-with-geneseeq-for-in-vitro-diagnostic-ngs-kit-in-china
  • https://seekingalpha.com/symbol/ILMN

SOLID TUMORS Solid tumors are remarkably diverse in their cellular origins and developmental stages. Comprehensive genomic profiling is needed for solid tumor specimens in order to capture their cellular and/or molecular heterogeneities. Our pan-cancer gene panels for all solid tumors and cancer-type specific genetic tests can meet all your clinical needs for precision medicine.

Merck and Gilead announce partnership for long-acting HIV treatments

Merck and Gilead announce partnership for long-acting HIV treatments

Merck and Gilead announce partnership for long-acting HIV treatments

 

March 15, 2021

Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV

–  Collaboration to Focus on Oral and Injectable Formulations of Lenacapavir and Islatravir –

–  Agreement Brings Together Potentially Complementary Medicines in Late-Stage Development with the Goal to Provide Innovative, Long-Acting Treatments in HIV –

FOSTER CITY, Calif. & KENILWORTH, N.J.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that they have entered into an agreement to co-develop and co-commercialize long-acting treatments in HIV that combine Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir,into a two-drug regimen with the potential to provide new, meaningful treatment options for people living with HIV. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210315005226/en/  


Islatravir and lenacapavir are both potentially first-in-class medicines in late-stage clinical trials, with significant clinical data generated to date. Both medicines have long half-lives and have demonstrated activity at low dosages in clinical studies, which support development as an investigational combination regimen with long-acting formulations, both oral and injectable.

The first clinical studies of the oral combination are expected to begin in the second half of 2021. Under the terms of the agreement, Gilead and Merck will work as partners, sharing operational responsibilities, as well as development, commercialization and marketing costs, and any future revenues.

Merck and Gilead seek to build on their legacies of transforming HIV care by focusing on long-acting therapies, which may represent a meaningful innovation in HIV drug development. While daily, single tablet regimens are available for people living with HIV, options that would allow for less frequent, oral dosing or infrequent injections rather than daily dosing have the potential to address preference considerations, as well as issues associated with adherence and privacy. 


Terms of the Collaboration

Under the terms of the agreement, Gilead and Merck will co-develop and co-commercialize long-acting products to treat people living with HIV that combine Gilead’s proprietary investigational capsid inhibitor, lenacapavir, and Merck’s proprietary investigational nucleoside reverse transcriptase translocation inhibitor, islatravir. The collaboration will initially focus on long-acting oral formulations and long-acting injectable formulations of these combination products, with other formulations potentially added to the collaboration as mutually agreed. 


About Islatravir (MK-8591)

Islatravir (formerly MK-8591) is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) that exhibits both translocation inhibition (which prevents nucleotide binding and incorporation to the DNA chain, resulting in immediate chain termination) and delayed chain termination (which prevents nucleotide incorporation even in the event of translocation). Islatravir is currently being evaluated for the treatment of HIV-1 infection in combination with other antiretrovirals, including the ILLUMINATE clinical trials program for oral, once-daily treatment. Islatravir is also being studied for preexposure prophylaxis (PrEP) of HIV-1 infection as a single agent across a variety of formulations, including the IMPOWER clinical trials evaluating an oral once-monthly regimen. In 2012, Merck licensed islatravir (4’-ethynyl-2-fluoro-2’-deoxyadenosine or EFdA) from the Yamasa Corporation based in Choshi, Japan.


About Lenacapavir

Lenacapavir is a novel investigational capsid inhibitor that interrupts the activity of HIV capsid, a protein that surrounds and protects the virus’ genetic material and essential enzymes. In in vitro studies, lenacapavir interrupts multiple distinct stages of the viral lifecycle, potentially preventing the virus from becoming infectious and gaining access to uninfected cells.

The safety, efficacy and dosing of lenacapavir are being evaluated in multiple ongoing clinical studies. Data presented at AIDS 2020 from the ongoing Phase 1 study support subcutaneous every six-month administration of lenacapavir for both HIV treatment and prevention studies. During IDWeek 2020, the company announced it would be evaluating the use of lenacapavir among cisgender women as an injectable PrEP option administered every six months. An additional lenacapavir for PrEP study in men who have sex with men and persons of trans experience is planned. Both studies are expected to begin in 2021.


 For more information about Gilead, please visit the company’s website at www.gilead.com. 


 For more information, visit www.merck.com  


 

Merck and Gilead announce partnership for long-acting HIV treatments

Mar. 15, 2021 10:50 AM ET

Merck & Co., Inc. (MRK)

By: Dulan Lokuwithana, SA News Editor15 Comments

  • Merck (MRK +1.2%) has partnered with Gilead Sciences (GILD +0.8%) to co-develop and co-commercialize long-acting treatments targeting people living with HIV.
  • https://seekingalpha.com/news/3672687-merck-and-gilead-partnership-for-long-acting-hiv-treatments
  • https://seekingalpha.com/symbol/GILD
  • https://seekingalpha.com/symbol/MRK

Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV Save March 15, 2021 6:45 am EST Collaboration to Focus on Oral and Injectable Formulations of Lenacapavir and Islatravir Agreement Brings Together Potentially Complementary Medicines in Late-Stage Development with the Goal to Provide Innovative, Long-Acting Treatments in HIV Foster City, Calif. and Kenilworth N.J. – March 15, 2021 – Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK

Lilly and Biolojic Design Announce Research Collaboration

Merck and Gilead announce partnership for long-acting HIV treatments

Merck and Gilead announce partnership for long-acting HIV treatments

 

Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes

March 8, 2021

Download PDF

Biolojic is eligible to receive up to $121 million, consisting of potential milestones and a promissory note, as well as tiered royalties

INDIANAPOLIS and TEL AVIV, March 8, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Biolojic Design Ltd. ("Biolojic"), a biotechnology company that computationally designs functional antibodies, today announced a research collaboration and license agreement that will leverage Biolojic's AI-based multibody platform to discover and develop a potential novel antibody-based therapy for the treatment of diabetes.


 Under the terms of the agreement, Lilly will pay research fees associated with the collaboration and additionally, Biolojic is eligible to receive up to a total of $121 million, consisting of potential development and commercialization milestones and a promissory note that may be convertible into Biolojic equity at a future date. Biolojic is also eligible to receive tiered royalties in the low- to mid-single digits on product sales should Lilly successfully commercialize a therapy from the collaboration. 


 To learn more, please visit www.biolojic.com. 


 To learn more about Lilly, please visit us at www.lilly.com 


 View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-and-biolojic-design-announce-research-collaboration-to-discover-and-develop-antibody-therapies-for-diabetes-301242715.html 

 

Lilly to collaborate with Biolojic Design to develop diabetes antibody therapies

Mar. 08, 2021 5:20 PM ET

Eli Lilly and Company (LLY)

By: Jonathan M Block, SA News Editor

  • Eli Lilly and Company (NYSE:LLY) has inked a research collaboration agreement with privately held Biolojic Design to leverage the latter's artificial intelligence-based multibody platform to discover novel antibody therapies for diabetes.

https://seekingalpha.com/news/3670507-lilly-to-collaborate-with-biolojic-design-to-develop-diabetes-antibody-therapies


https://seekingalpha.com/symbol/LLY


BIOLOJIC PIPELINE Biolojic’s pipeline focuses on targets and pathways where epitope specificity and dual target engagement are key for efficacy.

Exelixis Enters into Exclusive License Agreement with WuXi Biologics

Merck and Gilead announce partnership for long-acting HIV treatments

Exelixis Enters into Exclusive License Agreement with WuXi Biologics

 Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline

PDF Version

– Exelixis has exclusive license to panel of monoclonal antibodies against an undisclosed oncology target for biologics applications, leveraging WuXi Biologics integrated technology platforms –

– In addition to a modest upfront payment, WuXi Biologics is eligible for potential milestones and royalties on net sales of potential products –

ALAMEDA, Calif. & SHANGHAI--(BUSINESS WIRE)--Mar. 8, 2021-- Exelixis, Inc. (Nasdaq: EXEL) and WuXi Biologics (“WuXi Bio”) (2269.HK) today announced the companies have entered into an exclusive license agreement to support the continued expansion of Exelixis’ oncology biologics pipeline. The agreement is the latest in a series of biologics-focused transactions for Exelixis as the company builds out its pipeline behind CABOMETYX® (cabozantinib), its flagship product and global oncology franchise, which received its fourth approval from the U.S. Food and Drug Administration in January.

This press release features multimedia. 


View the full release here: https://www.businesswire.com/news/home/20210308005465/en/ 


Under the terms of the agreement, Exelixis will make a modest upfront payment to WuXi Bio in exchange for an exclusive license to a panel of monoclonal antibodies to a preclinically validated target, discovered based on WuXi Bio’s integrated technology platforms, for the development of antibody-drug conjugate, bispecific, and certain other novel tumor-targeting biologics applications. WuXi Bio will be eligible for development and commercialization milestones, as well as tiered royalties on net sales of any potential products commercialized from the panel. 


 For more information about WuXi Biologics, please visit: www.wuxibiologics.com.  


For more information about Exelixis, please visit www.exelixis.com  


Exelixis enters WuXi Biologics deal in oncology pipeline push

Mar. 08, 2021 11:36 AM ET Exelixis, Inc. (EXEL)

By: Aakash Babu, SA News Editor

Exelixis (EXEL -0.7%) and WuXi Biologics tie up in an exclusive license agreement to support the continued expansion of Exelixis’ oncology biologics pipeline.

https://seekingalpha.com/news/3670323-exelixis-enters-wuxi-biologics-deal-in-oncology-pipeline-push


https://seekingalpha.com/symbol/EXEL


https://seekingalpha.com/symbol/WXXWY

Mar. 08, 2021 Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline Exelixis has exclusive license to panel of monoclonal antibodies against an undisclosed oncology target for biologics applications, leveraging WuXi Biologics integrated technology platforms In addition to a modest upfront payment, WuXi Biologics is eligible for potential milestones and royalties on net sales of potential products SHANGHAI and ALAMEDA, Calif. March 8, 2021 –WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics technology platforms, and Exelixis, Inc. (Nasdaq: EXEL) today announced the companies have entered into an exclusive license agreement to support the continued expansion of Exelixis’ oncology biologics pipeline. The agreement is the latest in a series of biologics-focused transactions for Exelixis as the company builds out its pipeline behind CABOMETYX® (cabozantinib), its flagship product and global oncology franchise, which received its fourth approval from the U.S. Food and Drug Administration in January.

Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash

BIOGEN TO BUILD A NEW GENE THERAPY MANUFACTURING FACILITY IN RESEARCH TRIANGLE PARK, NORTH CAROLINA

Exelixis Enters into Exclusive License Agreement with WuXi Biologics

 

Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash

Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer Mortality Worldwide
Bemarituzumab is a Strong Strategic Fit With Amgen's Innovative Oncology Portfolio
Amgen to Host Investor Call at 10:30 a.m. EST

THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., March 4, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement under which Amgen will acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of approximately $1.9 billion. This acquisition adds Five Prime's innovative pipeline to Amgen's leading oncology portfolio.

 

About FGFR2b
The fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) pathway is implicated in the development and growth of cancer cells. FGFR2b is a splice variant of FGFR2 which can be found in tumors of epithelial origin. Data from the FIGHT trial suggests that approximately 30 percent of patients with non-HER2 positive gastroesophageal cancers overexpress FGFR2b.1 FGFR2b has also been shown to be overexpressed in numerous other cancers, including lung, breast, ovarian and other cancers.

About Bemarituzumab
Bemarituzumab (anti-FGFR2b) is a first-in-class targeted antibody that blocks fibroblast growth factors (FGFs) from binding and activating FGFR2b, inhibiting several downstream pro-tumor signaling pathways and potentially slowing cancer progression. Five Prime Therapeutics granted an exclusive license to Zai Lab Limited to develop and commercialize bemarituzumab in Greater China, and Zai Lab collaborated with Five Prime Therapeutics on the Phase 2 FIGHT trial in Greater China.


 For more information, visit www.amgen.com  

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/amgen-to-acquire-five-prime-therapeutics-for-1-9-billion-in-cash-301240358.html

SOURCE Amgen

 

Amgen to acquire Five Prime Therapeutics for $1.9B

Mar. 04, 2021 9:00 AM ET

Amgen Inc. (AMGN)

By: Mamta Mayani, SA News Editor2 Comments

  • Amgen (NASDAQ:AMGN) and Five Prime Therapeutics (NASDAQ:FPRX) ink merger agreement under which, AMGN will acquire Five Prime for $38.00/share in cash, representing an equity value of ~$1.9B. This acquisition adds Five Prime's innovative pipeline to Amgen's oncology portfolio with a promising late-stage candidate, bemarituzumab.

https://seekingalpha.com/news/3669372-amgen-to-acquire-five-prime-therapeutics-for-19b


https://seekingalpha.com/symbol/FPRX


https://seekingalpha.com/symbol/AMGN


Five Prime’s pipeline includes investigational immuno-oncology and targeted therapies in preclinical and clinical development for multiple solid tumors

ARCALYST®(rilonacept)

BIOGEN TO BUILD A NEW GENE THERAPY MANUFACTURING FACILITY IN RESEARCH TRIANGLE PARK, NORTH CAROLINA

BIOGEN TO BUILD A NEW GENE THERAPY MANUFACTURING FACILITY IN RESEARCH TRIANGLE PARK, NORTH CAROLINA

 

Regeneron and Kiniksa sign commercial supply agreement for Rilonacept

Mar. 03, 2021 5:07 PM ET

Kiniksa Pharmaceuticals, Ltd. (KNSA)

By: Dulan Lokuwithana, SA News Editor1 Comment

  • Kiniksa Pharmaceuticals (NASDAQ:KNSA) has announced a commercial supply agreement with Regeneron (NASDAQ:REGN) giving the latter the exclusive right to manufacture and supply rilonacept for Kiniksa’s U.K. subsidiary.

 

Rilonacept  

ARCALYST®
(rilonacept) INJECTION

 

Indication

ARCALYST® (rilonacept) Injection for Subcutaneous Use is used to treat adults and children 12 years of age and older with Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS).

 

Rilonacept

https://www.kiniksa.com/our-pipeline/rilonacept/


https://www.arcalyst.com/


https://www.regeneron.com/

https://seekingalpha.com/symbol/REGN


https://www.kiniksa.com/

https://seekingalpha.com/symbol/KNSA


ARCALYST® (rilonacept) is a prescription medicine called an interleukin-1 (IL-1) blocker. ARCALYST is used to treat adults and children 12 years of age and older with Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). ARCALYST can affect your immune system. ARCALYST can lower the ability of your immune system to fight infections. Serious infections, including life-threatening infections and death have happened in patients taking ARCALYST. Taking ARCALYST can make you more likely to get infections, including life-threatening serious infections, or may make any infection that you have worse.

BIOGEN TO BUILD A NEW GENE THERAPY MANUFACTURING FACILITY IN RESEARCH TRIANGLE PARK, NORTH CAROLINA

BIOGEN TO BUILD A NEW GENE THERAPY MANUFACTURING FACILITY IN RESEARCH TRIANGLE PARK, NORTH CAROLINA

BIOGEN TO BUILD A NEW GENE THERAPY MANUFACTURING FACILITY IN RESEARCH TRIANGLE PARK, NORTH CAROLINA

 

BIOGEN ANNOUNCES PLANS TO BUILD A NEW, STATE-OF-THE-ART GENE THERAPY MANUFACTURING FACILITY IN RESEARCH TRIANGLE PARK, NORTH CAROLINA

March 4, 2021 at 7:48 AM EST

  • The innovative and scalable gene therapy manufacturing facility will support Biogen’s plan to advance its gene therapy portfolio
  • The new facility is expected to employ approximately 90 people and to be operational by 2023

CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced its plans to build a new gene therapy manufacturing facility at its Research Triangle Park (RTP) manufacturing campuses in North Carolina to support its growing gene therapy pipeline across multiple therapeutic areas.

 

As pioneers in neuroscience, Biogen is pursuing multiple modalities with the aim of bringing life-saving medicines to those who suffer from serious neurological and neurodegenerative diseases. With this new facility, Biogen is investing in robust and scalable gene therapy manufacturing with the goal of ensuring reliable supply to patients worldwide. Gene therapy is an emerging therapeutic modality that may be suitable for a growing list of genetically validated targets in neuroscience.

“We plan to build differentiated, sustainable and advanced manufacturing capabilities to support our gene therapy programs and collaborations,” said Nicole Murphy, Senior Vice President, Global Manufacturing and Technical Operations. “This additional investment underscores our commitment to RTP and our mission to deliver a reliable supply of high-quality medicines to the patients we serve. We are poised with a diverse workforce that is passionate about making a difference in the lives of patients and we look forward to welcoming new colleagues from the community to join us in that mission.”

Through the new facility, Biogen aims to continue its investment in North Carolina and expand its existing operations and combined workforce of approximately 1,900 employees at both campuses in RTP. Biogen anticipates that the new facility will create approximately 90 new jobs, with an estimated total investment of approximately $200 million. Biogen selected RTP for this new facility given the region’s diverse pool of talent and the company’s 26-year track record of attracting highly qualified and passionate employees in North Carolina. Biogen’s priority is to continue to foster and enable a diverse and inclusive workforce – representing age, gender, sexual identity, race, ethnicity, Veterans, and people with disabilities – that reflects the communities where we operate and the patients who we serve.

The site will be 175,000 square feet and designed in compliance with the most advanced sustainability standards regarding energy use, waste management and water consumption.

 

Biogen to build new gene therapy facility

Mar. 04, 2021 8:18 AM ET

Biogen Inc. (BIIB)By: Aakash Babu, SA News Editor

  • Biogen (NASDAQ:BIIB) announces plans to build a new gene therapy manufacturing facility at its Research Triangle Park (RTP) manufacturing campuses in North Carolina to support its growing gene therapy pipeline across multiple therapeutic areas.

https://seekingalpha.com/news/3669331-biogen-to-build-new-gene-therapy-facility


https://seekingalpha.com/symbol/BIIB


Pipeline

BiotechVortex™

Enlivex and Mount Sinai Health System Announce Research Collaboration

Enlivex and Mount Sinai Health System Announce Research Collaboration

Enlivex and Mount Sinai Health System Announce Research Collaboration

  03/01/2021Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors

-- Collaboration aims to evaluate the potential of Allocetra™ in combination with immune-checkpoint inhibitors in solid cancer patients that do not respond to stand-alone checkpoint inhibitor therapies --

Nes Ziona, Israel, March 01, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, and Mount Sinai Health System, one of the world's leading academic health systems, today announced a new research collaboration for the development of clinical strategies for Allocetra™ with checkpoint inhibitors.  Allocetra™ is a macrophage-reprogramming immunotherapy product candidate currently in clinical development by Enlivex for the potential treatment of life-threatening immune-mediated diseases.


 Under the strategic collaboration agreement, the parties have agreed to develop and execute a pre-clinical program to investigate the potential synergies between Allocetra™ and commercially approved checkpoint inhibitor therapies for select solid cancers. 


 

ABOUT ALLOCETRATM

AllocetraTM is a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as "unmet medical needs", as a stand-alone therapy or in combination with leading therapeutic agents.


 For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube. 


 

Allocetra™ Macrophage reprogramming

https://enlivex.com/allocetra/


 

Enlivex and Mount Sinai Health System announce research collaboration deal

Mar. 01, 2021 8:10 AM ET

Enlivex Therapeutics Ltd. (ENLV)

By: Aakash Babu, SA News Editor

  • Enlivex Therapeutics (NASDAQ:ENLV) and New York City's largest academic medical system Mount Sinai Health System announce a new research collaboration for the development of clinical strategies for Allocetra with checkpoint inhibitors.

https://seekingalpha.com/news/3667522-enlivex-and-mount-sinai-health-system-announce-research-collaboration-deal




https://seekingalpha.com/symbol/ENLV



Allocetra™ Macrophage reprogramming

fixed doses of COM701 and Opdivo®

Enlivex and Mount Sinai Health System Announce Research Collaboration

Enlivex and Mount Sinai Health System Announce Research Collaboration

 

Compugen Expands Clinical Collaboration Agreement with Bristol Myers Squibb with Phase 1b Combination Study of COM701 with Opdivo®

February 22, 2021Cohort expansion study expected to commence in the second quarter of 2021

HOLON, Israel, Feb. 22, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today the expansion of its clinical collaboration agreement with Bristol Myers Squibb. Under the amended agreement, Bristol Myers Squibb will supply Opdivo® (nivolumab), its PD-1 inhibitor, for Compugen's Phase 1b cohort expansion study designed to assess COM701, Compugen's first-in-class anti-PVRIG antibody, in combination with Opdivo® in selected cancer indications. Study initiation is expected in the second quarter of 2021.


 For additional information, please visit Compugen's corporate website at www.cgen.com. 

  

View original content

:http://www.prnewswire.com/news-releases/compugen-expands-clinical-collaboration-agreement-with-bristol-myers-squibb-with-phase-1b-combination-study-of-com701-with-opdivo-301232339.html

SOURCE Compugen Ltd.


  fixed doses of COM701 and Opdivo® 

Dr. Cohen-Dayag continued, "Bristol Myers Squibb continues to be a valued partner for our COM701 clinical program as we advance the immunotherapy treatment landscape of patients with cancer."

Under the terms of the amendment, Bristol Myers Squibb will continue to supply Opdivo® to the Compugen-sponsored study. The Phase 1b study, a part of Compugen's COM701 monotherapy and combination therapy dose escalation and expansion program (NCT03667716), will examine fixed doses of COM701 and Opdivo®, as determined by Compugen's Phase 1a combination dose escalation study. Based on Compugen's translational analyses and preliminary antitumor activity in dose escalation, the study will enroll patients with ovarian, breast, endometrial and microsatellite-stable colorectal cancers.


https://cgen.com/pipeline/

 

Compugen expands deal with Bristol Myers for phase 1b COM701 combo study

Feb. 22, 2021 12:12 PM ET

Compugen Ltd. (CGEN)

By: Aakash Babu, SA News Editor

  • Compugen (CGEN -5.3%) announces the expansion of its clinical collaboration agreement with Bristol Myers Squibb (BMY -0.1%) to supply blockbuster cancer treatment Opdivo (nivolumab),  for Compugen's Phase 1b cohort expansion study to assess COM701, an anti-PVRIG antibody, in combination with Opdivo in selected cancer indications.

https://seekingalpha.com/news/3664386-compugen-expands-deal-with-bristol-myers-for-phase-1b-com701-combo-study


https://seekingalpha.com/symbol/CGEN


https://seekingalpha.com/symbol/BMY

Compugen’s lead candidate, COM701, is a first-in-class immunotherapy targeting PVRIG, a novel immune checkpoint that our team computationally discovered and validated in preclinical studies. Clinical data of COM701, as a monotherapy and in combination with PD-1 blockers, have demonstrated initial signs of antitumor activity, with encouraging disease control rate, durability of responses and safety and tolerability in patients that have progressed or failed on many prior lines of therapy. Learn more about the most recent clinical data on COM701 here.

Compugen’s Triple Checkpoint Hypothesis

Enlivex and Mount Sinai Health System Announce Research Collaboration

Compugen’s Triple Checkpoint Hypothesis

 

Compugen’s Triple Checkpoint Hypothesis

•Jan 20, 2021     Compugen Ltd.
 

 At Compugen, we believe that the PVRIG pathway we discovered is a potential paradigm shifting target to enhance patient responses to cancer immunotherapies and may provide new treatment options as monotherapy or in combination with other immune checkpoints to expand the reach of cancer immunotherapies to new patient populations. Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. Compugen’s lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen’s antibody targeting TIGIT, is in a Phase 1 clinical study. Compugen’s therapeutic pipeline also includes early stage immuno-oncology programs focused largely on myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen’s corporate website at www.cgen.com. 





Compugen’s lead candidate, COM701, is a first-in-class immunotherapy targeting PVRIG, a novel immune checkpoint that our team computationally discovered and validated in preclinical studies. Clinical data of COM701, as a monotherapy and in combination with PD-1 blockers, have demonstrated initial signs of antitumor activity, with encouraging disease control rate, durability of responses and safety and tolerability in patients that have progressed or failed on many prior lines of therapy. Learn more about the most recent clinical data on COM701 here.

Merck to Acquire Pandion Therapeutics

Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab)

Compugen’s Triple Checkpoint Hypothesis

 

Merck to Acquire Pandion Therapeutics


February 25, 2021 6:45 am EST

Acquisition Adds Pipeline of Candidates Targeting a Broad Range of Autoimmune Diseases

KENILWORTH, N.J & WATERTOWN, Mass.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Pandion Therapeutics, Inc. (Nasdaq: PAND) today announced that the companies have entered into a definitive agreement, under which Merck, through a subsidiary, will acquire Pandion, a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, for $60 per share in cash. This represents an approximate total equity value of $1.85 billion.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005318/en/


  

About PT101

PT101 is an engineered IL-2 mutein fused to a protein backbone designed to selectively activate and expand regulatory T cells for the treatment of autoimmune diseases. In autoimmune diseases, the immune system inappropriately attacks a host’s cells, and targeting Tregs could allow the immune system to regain control and return to homeostasis. PT101 has completed a Phase 1a clinical trial, which achieved its primary objective of safety and tolerability. In the trial, PT101 demonstrated proof of mechanism by selectively expanding Tregs in healthy volunteers.


 For more information, please visit www.pandiontx.com  


  For more information, visit www.merck.com  


 

Pandion is focused on developing therapeutics for a wide range of autoimmune and inflammatory indications.

https://pandiontx.com/pipeline/overview/


 

Merck to acquire Pandion for $2 billion

Feb. 25, 2021 7:09 AM ET 

Merck & Co., Inc. (MRK)

By: Dulan Lokuwithana, SA News Editor

1 Comment

  • Merck (NYSE:MRK) has agreed to acquire Pandion Therapeutics (NASDAQ:PAND) for $60 per share in an all-cash deal valuing Pandion at $1.85B.

https://seekingalpha.com/news/3666246-merck-to-acquire-pandion-in-a-deal-valued-at-2-billion


https://seekingalpha.com/symbol/PAND


https://seekingalpha.com/symbol/MRK


Pandion is focused on developing therapeutics for a wide range of autoimmune and inflammatory indications.

RIPK1 Inhibitors

Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab)

Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab)

 

Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases

Download as PDF

February 18, 2021 6:30am EST

- Lilly will obtain an exclusive worldwide license to Rigel's RIPK1 inhibitors, including Rigel's Phase 2-ready molecule R552, in all indications

- Rigel will receive an upfront cash payment of $125 million, with the potential for up to an additional $835 million in future development, regulatory, and commercial milestones

INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., Feb. 18, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases. Pursuant to the collaboration, Lilly will also lead all clinical development of brain penetrating RIPK1 inhibitors in central nervous system (CNS) diseases.

  

RIPK1 Inhibitors

Rigel's lead RIPK1 inhibitor, R552, has completed Phase 1 clinical trials and will begin Phase 2 clinical trials in 2021 as part of the collaboration.  Rigel also has ongoing pre-clinical activities with its lead CNS penetrant RIPK1 inhibitor candidates.

Under the terms of the agreement, Lilly will pay an upfront cash payment to Rigel of $125 million. Rigel may also be eligible to receive up to $835 million in potential development, regulatory, and commercial milestone payments, as well as tiered royalties ranging from the mid-single digit to high-teens that will vary depending upon Rigel's clinical development investment. Lilly and Rigel will co-develop R552 at specified contribution levels. Lilly will be responsible for all costs of global commercialization for R552, and Rigel will have the right to co-commercialize R552 in the U.S. Lilly will be solely responsible for all clinical development and commercialization of brain penetrating RIPK1 inhibitors in CNS indications.

RIPK1 is a critical signaling protein implicated in a broad range of key inflammatory cellular processes including necroptosis, a type of regulated cell death, and cytokine production. In necroptosis, cells rupture leading to the dispersion of cell contents which can trigger an immune response and enhance inflammation. Inhibiting RIPK1 may be a new approach to treating various autoimmune, inflammatory, and neurodegenerative disorders. In pre-clinical studies, Rigel's R552 demonstrated prevention of joint and skin inflammation in a RIPK1-mediated murine model of inflammation and tissue damage.


 To learn more about Rigel, please visit us at www.rigel.com. 


 To learn more about Lilly, please visit us at www.lilly.com.  

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-and-rigel-enter-strategic-collaboration-to-develop-ripk1-inhibitors-for-the-potential-treatment-of-immunological-and-neurodegenerative-diseases-301230502.html

SOURCE Eli Lilly and Company; Rigel Pharmaceuticals

Released February 18, 2021


 

Rigel shares surge 41% on RIPK1 inhibitors deal with Eli Lilly

Feb. 18, 2021 6:47 AM ET

Rigel Pharmaceuticals, Inc. (RIGL)

By: Mamta Mayani, SA News Editor7 Comments

  • Rigel Pharmaceuticals (NASDAQ:RIGL) soars 41% premarket after announcing a global license agreement and strategic collaboration Eli Lilly (NYSE:LLY) to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases.

https://seekingalpha.com/news/3663357-eli-lilly-rigel-team-up-to-develop-ripk1-inhibitors


https://seekingalpha.com/symbol/LLY


https://seekingalpha.com/symbol/RIGL



Pipeline

Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab)

Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab)

Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab)

  Feb 17, 2021PDF Version Nektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN)

SAN FRANCISCO, Feb. 17, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada) for a Phase 2/3 study of bempegaldesleukin (NKTR-214, BEMPEG), Nektar's investigational IL-2 pathway agent, in combination with Merck's KEYTRUDA® (pembrolizumab) for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (SCCHN) whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1).  The study is planned to start in the second half of 2021.


 Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab)  

 

"We are excited to advance the combination of BEMPEG plus KEYTRUDA to a Phase 2/3 study in first-line squamous cell carcinoma of the head and neck," said Jonathan Zalevsky, PhD, Chief R&D Officer at Nektar.  "Earlier studies of BEMPEG in combination with immune checkpoint inhibitors, also known as ICIs, evaluated in patients with immune-sensitive cancers have shown the potential to increase and deepen treatment responses as compared to historical rates for ICIs alone.  This collaboration with Merck will enable us to further explore the combination of BEMPEG with the leading checkpoint inhibitor therapy in the setting of advanced head and neck cancer." 

Under the terms of the agreement, Nektar will conduct the Phase 2/3 study, which is expected to enroll 500 patients with metastatic or recurrent SCCHN with PD-L1 expressing tumors.  Patients will be randomized to receive either the combination of BEMPEG plus pembrolizumab or pembrolizumab alone.  The Phase 2 portion of the study will include an interim analysis of overall response rate (ORR) after the first 200 patients enrolled have a minimum follow up of 4 months.  If the ORR passes a prespecified futility boundary, the study will continue, and the remaining 300 patients will be enrolled to the Phase 3 portion of the study.  The primary endpoints of the trial are ORR and overall survival (OS); progression free survival (PFS) is a secondary endpoint.

 

Bempegaldesleukin (NKTR-214)

https://www.nektar.com/pipeline/rd-pipeline/nktr-214

 

Nektar and Merck team up in mid-stage cancer combo study

Feb. 17, 2021 10:59 AM ET Nektar Therapeutics (NKTR) By: Aakash Babu, SA News Editor2 Comments

  • Nektar Therapeutics (NKTR +11.8%) has entered into a clinical trial collaboration and supply agreement with Merck (MRK +1.9%) for a Phase 2/3 study of Nektar's bempegaldesleukin in combination with Merck's blockbuster cancer drug KEYTRUDA for first-line treatment of certain patients with squamous cell carcinoma.

https://seekingalpha.com/news/3662897-nektar-and-merck-team-up-in-mid-stage-cancer-combo-study


https://www.nektar.com/

https://seekingalpha.com/symbol/NKTR



Bempegaldesleukin (NKTR-214)

GSK and Vir Biotechnology Expand Coronavirus Collaboration

BMY & Rockefeller Uni = License Agreement - SARS-CoV-2 Neutralizing Monoclonal Antibody Combination

BMY & Rockefeller Uni = License Agreement - SARS-CoV-2 Neutralizing Monoclonal Antibody Combination

  

GSK and Vir Biotechnology Expand Coronavirus Collaboration to Advance New Therapeutics for Influenza and Other Respiratory Viruses

02/17/21 at 7:04 AM ESTPDF Version

– Companies applying their combined expertise in immunology and infectious diseases to accelerate the development of promising monoclonal antibody candidates for influenza –

– Functional genomics collaboration expanded to include respiratory viruses, Vir’s unique technology, and access to GSK’s small molecule compounds –

– Additional exploration of up to three other antibodies for pathogens
beyond influenza and coronaviruses –

– GSK is increasing its equity investment by $120 million and making an upfront
payment of $225 million –

LONDON and SAN FRANCISCO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced they have signed a binding agreement to expand their existing collaboration to include the research and development of new therapies for influenza and other respiratory viruses.


 

About Vir’s Antibody Platform
Vir has a robust method for capitalizing on unusually successful immune responses naturally occurring in people who are protected from, or have recovered from, infectious diseases. The platform is used to identify rare antibodies from survivors that have the potential to treat and prevent rapidly evolving and/or previously untreatable pathogens via direct pathogen neutralization and immune system stimulation. Vir engineers the fully human antibodies that it discovers to enhance their therapeutic potential. This platform has been used to identify and develop antibodies for pathogens including SARS-CoV-2, hepatitis B virus, influenza A, Ebola (mAb114, approved for use in the U.S. as EbangaTM and marketed by Ridgeback Therapeutics LP), malaria and others.

About VIR-2482
VIR-2482 is an investigational intramuscularly administered influenza A-neutralizing monoclonal antibody. In vitro, it has been shown to cover all major strains of influenza A that have arisen since the 1918 Spanish flu pandemic. VIR-2482 is designed as a universal prophylactic for influenza A. It has the potential to overcome the limitations of current flu vaccines and lead to meaningfully higher levels of protection due to its broad strain coverage and because it does not rely on an individual to create their own protective antibody response. VIR-2482 has been half-life engineered so that a single dose has the potential to last the entire flu season.

About VIR-7831 / GSK4182137
VIR-7831 is an investigational dual-action SARS-CoV-2 monoclonal antibody. Preclinical data suggest it has the potential to both block viral entry into healthy cells and clear infected cells. The antibody binds to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. VIR-7831 also has been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.

About VIR-7832 / GSK4182136
VIR-7832 is an investigational dual-action SARS-CoV-2 monoclonal antibody. Preclinical data suggest it has the potential to both block viral entry into healthy cells and an enhanced ability to clear infected cells. The antibody binds to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. VIR-7832 also has been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life. Importantly, VIR-7832 has also been engineered to potentially enhance virus-specific T cell function, which could help treat and/or prevent COVID-19 infection.

About the Vir and GSK Collaboration
In April 2020, Vir and GSK entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies are leveraging GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They are also applying their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.


 For more information, please visit www.vir.bio. 


 For further information please visit www.gsk.com/about-us. 


 

GSK, Vir Bio to advance new therapies for influenza and other respiratory viruses

Feb. 17, 2021 7:47 AM ETVir Biotechnology, Inc. (VIR)By: Mamta Mayani, SA News Editor

  • Vir Biotechnology (NASDAQ:VIR) jumps 12% premarket after signing a binding agreement with GlaxoSmithKline (NYSE:GSK) to expand their existing collaboration to include the R&D of new therapies for influenza and other respiratory viruses.

https://seekingalpha.com/news/3662763-gsk-vir-bio-to-advance-therapies-for-respiratory-diseases


https://seekingalpha.com/symbol/GSK


https://seekingalpha.com/symbol/VIR






We are developing a broad portfolio of product candidates that are designed to combat serious, global infectious diseases in entirely new ways, creating medicines that will have a meaningful impact on people around the world.

BMY & Rockefeller Uni = License Agreement - SARS-CoV-2 Neutralizing Monoclonal Antibody Combination

BMY & Rockefeller Uni = License Agreement - SARS-CoV-2 Neutralizing Monoclonal Antibody Combination

BMY & Rockefeller Uni = License Agreement - SARS-CoV-2 Neutralizing Monoclonal Antibody Combination

  

Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19

02/03/2021CATEGORY: 

  • Corporate/Financial News

NEW YORK--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and The Rockefeller University today announced that they have entered into a definitive agreement under which Bristol Myers Squibb has been granted a global exclusive license to develop, manufacture and commercialize Rockefeller’s novel monoclonal antibody (“mAb”) duo treatment that neutralizes the SARS-CoV-2 virus for therapy or prevention of COVID-19.


  SARS-CoV-2 mAb Combo 

About SARS-CoV-2 mAb Combo

Rockefeller has discovered two complementary antibodies to the SARS-CoV-2 spike protein that synergistically neutralize the virus in vitro and in animal models. The two antibodies have shown activity against several known SARS-CoV-2 mutants and it is believed that their co-administration could reduce the possibility of mutant virus escape. The two antibodies are potentially unique as pertains to their long half-life in humans and high affinity for the spike protein. The longer half-life has been enabled by leveraging Xencor’s Fc engineering technology.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.

Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company.

About The Rockefeller University

The Rockefeller University is the world’s leading biomedical research university and is dedicated to conducting innovative, high-impact research to improve the understanding of life for the benefit of humanity. The university’s unique approach to science, with only 70 faculty, each selected for pursuit of highly innovative ideas, has led to many of the world’s most revolutionary and transformative contributions to biology and medicine. During Rockefeller’s 120-year history, Rockefeller scientists have won 26 Nobel Prizes, 24 Albert Lasker Medical Research Awards, and 20 National Medals of Science.


 View source version on businesswire.com: https://www.businesswire.com/news/home/20210203005253/en/ 


 COVID-19 research at Rockefeller 

https://covid-19-research.rockefeller.edu/

https://www.rockefeller.edu/


https://www.bms.com/

https://seekingalpha.com/symbol/BMY





COVID-19 research at Rockefeller

Lilly teams up with Vir Bio/GSK to evaluate bamlanivimab with VIR-7831 in COVID-19

BMY & Rockefeller Uni = License Agreement - SARS-CoV-2 Neutralizing Monoclonal Antibody Combination

Lilly teams up with Vir Bio/GSK to evaluate bamlanivimab with VIR-7831 in COVID-19

 

Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19

January 27, 2021 Download PDF

INDIANAPOLIS and SAN FRANCISCO and LONDON, Jan. 27, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced a collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate COVID-19. Lilly has expanded its ongoing BLAZE-4 trial to evaluate the administration of bamlanivimab (LY-CoV555) 700mg with VIR-7831 (also known as GSK4182136) 500mg, two neutralizing antibodies that bind to different epitopes of the SARS-CoV-2 spike protein. This unique collaboration marks the first time that monoclonal antibodies from separate companies will be brought together to explore potential outcomes.


 bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19 

 

Important Information about bamlanivimab 
Bamlanivimab has not been approved by the FDA for any use. It is not known if bamlanivimab is safe and effective for the treatment of COVID-19. 

Bamlanivimab is authorized under an Emergency Use Authorization only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of bamlanivimab under Section 564(b)(1) of the Act, 21 U.S.C § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Healthcare providers should review the Fact Sheet for information on the authorized use of bamlanivimab and mandatory requirements of the EUA. Please see the FDA Letter of Authorization, Fact Sheet for Healthcare Providers, and Fact Sheet for Patients, Parents, and Caregivers (English) (Spanish).

Authorized Use and Important Safety Information
Bamlanivimab 700 mg injection is authorized for use under EUA for treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.


 About BLAZE-4
BLAZE-4 (NCT04634409) is a randomized, double-blind, placebo-controlled trial designed to assess the efficacy and safety of bamlanivimab alone, and bamlanivimab with other neutralizing antibodies including VIR-7831 (GSK4182136) versus placebo for the treatment of symptomatic COVID-19 in the outpatient setting. Across all treatment arms, the trial will enroll an estimated 1,000 participants in the United States and Puerto Rico. 

 

About bamlanivimab
Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19. 

Lilly has successfully completed a Phase 1 study of bamlanivimab in hospitalized patients with COVID-19 (NCT04411628). A Phase 2/3 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is ongoing. In addition, bamlanivimab is being tested in the National Institutes of Health-led ACTIV-2 study in ambulatory COVID-19 patients.

Bamlanivimab is authorized in the U.S. for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test, who are at high risk for progressing to severe COVID-19 and/or hospitalization. Bamlanivimab should be administered as soon as possible after a positive COVID-19 test and within 10 days of symptom onset.

About etesevimab
Etesevimab (LY-CoV016, also known as JS016) is a recombinant, fully human monoclonal neutralizing antibody, which specifically binds to the SARS-CoV-2 surface spike protein receptor binding domain with high affinity and can block the binding of the virus to the ACE2 host cell surface receptor. Point mutations were introduced into the native human IgG1 antibody to mitigate effector function. Lilly licensed etesevimab from Junshi Biosciences after it was jointly developed by Junshi Biosciences and Institute of Microbiology, Chinese Academy of Science (IMCAS). Junshi Biosciences leads development in Greater China, while Lilly leads development in the rest of the world.

Lilly has successfully completed a Phase 1 study (NCT04441931) of etesevimab in healthy U.S. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity. A Phase 2/3 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing. Junshi Biosciences has completed a similar Phase 1 study in healthy volunteers in China and has initiated Phase 1b/2 trials in COVID-19 patients globally.

About VIR-7831 / GSK4182136
VIR-7831 (GSK4182136) is an investigational dual-action monoclonal antibody. Preclinical data suggest it has the potential to both block viral entry into healthy cells and clear infected cells. The antibody binds to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1 (the virus which causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. VIR-7831 also has been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.

The COMET clinical development program for VIR-7831 includes a planned Phase 3 trial for the prevention of symptomatic infection. VIR-7831 is also being evaluated in a sub-trial of the National Institutes of Health's (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Program Phase 3 clinical trial. This trial is designed to evaluate the safety and efficacy of VIR-7831 for the treatment of hospitalized adults with COVID-19. 


 To learn more about Lilly, please visit us at www.lilly.com  


 For further information please visit www.gsk.com/about-us.  


 For more information, please visit www.vir.bio.  


 View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-vir-biotechnology-and-gsk-announce-first-patient-dosed-in-expanded-blaze-4-trial-evaluating-bamlanivimab-ly-cov555-with-vir-7831-gsk4182136-for-covid-19-301216017.html 


 

Lilly teams up with Vir Bio/GSK to evaluate bamlanivimab with VIR-7831 in COVID-19

Jan. 27, 2021 7:07 AM ET Eli Lilly and Company (LLY) By: Mamta Mayani, SA News Editor

  • Eli Lilly (NYSE:LLY), Vir Biotechnology (NASDAQ:VIR) and GlaxoSmithKline (NYSE:GSK) have collaborated to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate symptoms.

https://seekingalpha.com/news/3654808-lilly-teams-up-with-vir-biogsk-to-evaluate-bamlanivimab-with-vir-7831-in-covid-19


Your COVID-19 Treatment Journey: Our Antibodies Might Help

Eli Lilly and Company 

https://www.lilly.com/news/stories/covid19-treatment-monoclonal-antibodies-infusion-resources   


https://seekingalpha.com/symbol/LLY



Your COVID-19 Treatment Journey: Our Antibodies Might Help Eli Lilly and Company

Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc

Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc

Lilly teams up with Vir Bio/GSK to evaluate bamlanivimab with VIR-7831 in COVID-19

 

Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader

February 03, 2021 Download PDF Adds high-growth commercial franchise to Neuroscience portfolio with Epidiolex®, the first and only FDA-approved prescription cannabidiol medicine and a potential near-term blockbuster
Enhanced product diversification of combined company expected to provide accelerated double-digit revenue growth
Anticipated to be accretive in first full year of combined operations and substantially accretive thereafter
Conference call today at 8:30 AM ET

DUBLIN and LONDON, Feb. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, or $6.7 billion net of GW cash. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close in the second quarter of 2021. 

 

About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the lives of patients with serious diseases — often with limited or no options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. Our focus is in neuroscience, including sleep and movement disorders, and in oncology, including hematologic malignancies and solid tumors. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.


About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX® (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX® for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia.


https://www.jazzpharma.com/science/pipeline/


 

Jazz to acquire GW Pharma in cash-and-stock deal valued at $7.2B

Feb. 03, 2021 8:03 AM ETJazz Pharmaceuticals plc (JAZZ)By: Dulan Lokuwithana, SA News Editor13 Comments

  • Jazz Pharmaceuticals (NASDAQ:JAZZ) is trading ~5.3% lower in the premarket after announcing that it has agreed to acquire GW Pharmaceuticals plc (NASDAQ:GWPH) for $220.00 per American Depositary Share.

https://seekingalpha.com/news/3657703-jazz-to-acquire-gw-pharma-in-cash-and-stock-deal-valued-at-72b


https://seekingalpha.com/symbol/JAZZ


https://www.gwpharm.com/

https://seekingalpha.com/symbol/GWPH


 Deals

Jazz Pharma to Buy Cannabinoid-Drug Maker for $7.2 Billion

By Timothy Annett and Tiffany Kary

February 3, 2021, 7:50 AM EST Updated on February 3, 2021, 10:25 AM EST

  • Terms represent 50% premium for U.K.-based GW Pharmaceuticals
  • GW’s Epidiolex was first cannabis-derived drug cleared by FDA

GW is a developer of cannabinoid-based medications for cancer pain, multiple sclerosis and other conditions. Photographer: Jason Alden/Bloomberg https://www.bloomberg.com/news/articles/2021-02-03/jazz-pharmaceuticals-to-buy-gw-for-7-2-billion-in-cash-stock?srnd=premium

GW is a developer of cannabinoid-based medications for cancer pain, multiple sclerosis and other conditions.

Pipeline

VERACYTE TO ACQUIRE DECIPHER BIOSCIENCES

Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc

Affimed Announces Collaboration with Roche

  VERACYTE TO ACQUIRE DECIPHER BIOSCIENCES Feb 3, 2021 PDF Version

Further solidifies global leadership in differentiated, genomics-driven cancer diagnostics

Expands TAM with presence in 7 of the 10 most common cancers

Expected to accelerate revenue growth

Tina Nova, Ph.D., Decipher Biosciences’ president and CEO, has left Veracyte’s board and will become Veracyte’s GM, urologic cancers

Investor conference call and webcast today at 8:00 a.m. Eastern Time

SOUTH SAN FRANCISCO, Calif., & SAN DIEGO, Calif.--(BUSINESS WIRE)--Feb. 3, 2021-- Veracyte, Inc. (Nasdaq: VCYT) and Decipher Biosciences, Inc., a commercial-stage precision oncology company focused on urologic cancers, today announced they have entered into a definitive agreement through which Veracyte will acquire Decipher, further solidifying Veracyte’s global leadership in the genomic cancer diagnostics market while accelerating revenue growth.

 

About Decipher Bioscience

Decipher Biosciences is a commercial-stage precision oncology company committed to improving patient care, initially focused on urologic cancers. Decipher’s novel prostate cancer genomic test, Decipher Prostate, provides valuable information about the underlying biology of a patient’s tumor, assisting physicians in their selection of an optimal therapy. Decipher’s differentiated approach measures the biological activity of a patient’s entire tumor genome, known as whole transcriptome analysis, and applies proprietary machine learning algorithms to help physicians improve therapy selection and accelerate adoption of new therapies into the standard of care. Decipher Biosciences is headquartered in San Diego, California.


About Veracyte

Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in thyroid cancer, lung cancer, breast cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping test is in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).


 View source version on businesswire.com: https://www.businesswire.com/news/home/20210203005354/en/ 


https://decipherbio.com/


 

Veracyte to acquire Decipher Biosciences

Feb. 03, 2021 7:42 AM ETVeracyte, Inc. (VCYT)By: Khyathi Dalal, SA News Editor

  • Veracyte (NASDAQ:VCYT) and Decipher Biosciences (DECI), commercial-stage precision oncology company focused on urologic cancers, inked a definitive acquisition agreement under which former will acquire the latter thereby solidifying Veracyte's global leadership in the genomic cancer diagnostics market while accelerating revenue growth.

https://seekingalpha.com/news/3657691-veracyte-to-acquire-decipher-biosciences


https://seekingalpha.com/symbol/VCYT



Discover Our Capabilities Our biopharma solutions: Enable clinical trials in earlier patient populations Reveal new biomarkers through comprehensive genomic profiling Derive insights from population-level genomics

Affimed Announces Collaboration with Roche

Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc

Affimed Announces Collaboration with Roche

 

Affimed Announces Collaboration with Roche to Study AFM24 in Combination with PD-L1 Checkpoint Inhibitor in EGFR Expressing Solid Tumors

Press Release - February 3, 2021

AFMD_Roche_ Agreement AFM24

Heidelberg, Germany, February 3, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has entered into a clinical research collaboration with Roche to explore the combination of Affimed’s innate cell engager (ICE®) AFM24 with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®).


 Affimed’s innate cell engager (ICE®) AFM24 with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®). 

 

Our Pipeline

Diverse pipeline of innate cell engagers designed to activate innate immunity

A number of clinical and preclinical programs are in development based on the ROCK® platform and our tetravalent bispecific immune cell engagers have already shown a favorable safety profile and promising signs of therapeutic efficacy.

https://www.affimed.com/rock-platform/pipeline/


 

TECENTRIQ may work with your immune system to fight cancer

https://www.tecentriq.com/ 

 

Affimed and Roche collaborate to study AFM24 in solid tumors

Feb. 03, 2021 7:03 AM ET

Affimed N.V. (AFMD)

By: Dulan Lokuwithana, SA News Editor

  • Affimed N.V. (NASDAQ:AFMD) has surged ~10.6% in the premarket after announcing that it has entered a research collaboration with Roche (OTCQX:RHHBY) to study its innate cell engager (ICE®) AFM24 with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®).

https://seekingalpha.com/news/3657663-affimed-and-roche-collaborate-to-study-afm24-in-solid-tumors


https://seekingalpha.com/symbol/AFMD

https://seekingalpha.com/symbol/RHHBY



Our Pipeline Diverse pipeline of innate cell engagers designed to activate innate immunity A number of clinical and preclinical programs are in development based on the ROCK® platform and our tetravalent bispecific immune cell engagers have already shown a favorable safety profile and promising signs of therapeutic efficacy.

BiotechVortex™

Gilead and Vir Biotechnology Establish Clinical Collaboration

Gilead and Vir Biotechnology Establish Clinical Collaboration

Gilead and Vir Biotechnology Establish Clinical Collaboration

 

January 12, 2021

Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus

-- First Phase 2 Clinical Trial to Combine Immunomodulation and Antigen Suppression Approaches in HBV Cure Research --

FOSTER CITY, Calif. & SAN FRANCISCO--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NASDAQ: GILD) and Vir Biotechnology, Inc. (NASDAQ: VIR) today announced that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing a functional cure for chronic hepatitis B virus (HBV).  

 

Gilead and Vir Biotechnology Establish Clinical Collaboration  

The companies plan to initiate a Phase 2 trial evaluating combination therapy for both treatment-experienced and treatment-naïve people living with HBV. The multi-arm trial will evaluate different combinations of selgantolimod, Gilead’s investigational TLR-8 agonist; VIR-2218, Vir’s investigational small interfering ribonucleic acid (siRNA); and a commercially-sourced, marketed PD-1 antagonist. People in the trial with HBV treatment experience may also receive Gilead’s Vemlidy® (tenofovir alafenamide fumarate, TAF). The primary outcome of the study will be the proportion of patients achieving a functional cure, defined as an off-therapy loss of hepatitis B surface antigen (HBsAg) and HBV DNA from the serum.

Both companies retain full rights to their individual product candidates and will discuss the potential path forward for any future combination studies based on the outcome of the Phase 2 trial.


 VEMLIDY  

INDICATION

VEMLIDY is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.

Please click here to see full Prescribing Information for VEMLIDY, including BOXED WARNING.

https://www.vemlidy.com/


 Please see Important Facts about VEMLIDY, including important warnings. 


 For more information, please visit www.vir.bio. 


  For more information on Gilead Sciences, please visit the company’s website at www.gilead.com. 

 

Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus

Tue January 12, 2021 8:00 AM|GlobeNewswire|About: GILD, VIR

– First Phase 2 clinical trial to combine immunomodulation and antigen suppression approaches in HBV cure research –

FOSTER CITY, Calif. and SAN FRANCISCO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Gilead Sciences, Inc. (GILD) and Vir Biotechnology, Inc. (VIR) today announced that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing a functional cure for chronic hepatitis B virus (HBV).

https://seekingalpha.com/pr/18147900-gilead-and-vir-biotechnology-establish-clinical-collaboration-to-explore-combination 

 

Gilead and VIR Biotechnology tie up in chronic hepatitis B virus cure setting

Jan. 12, 2021 8:12 AM ET Gilead Sciences, Inc. (GILD) By: Aakash Babu, SA News Editor1 Comment

  • Gilead Sciences (NASDAQ:GILD) and Vir Biotechnology (NASDAQ:VIR) announces that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing a functional cure for chronic hepatitis B virus (HBV).

https://seekingalpha.com/news/3650652-gilead-and-vir-biotechnology-tie-up-in-chronic-hepatitis-b-virus-cure-setting


https://seekingalpha.com/symbol/GILD


https://seekingalpha.com/symbol/VIR


WHAT IS VEMLIDY? VEMLIDY is a prescription medicine used to treat chronic (long-lasting) hepatitis B virus (HBV) in adults with stable (compensated) liver disease. VEMLIDY may lower the amount of HBV in your body. VEMLIDY may improve the condition of your liver.

Lilly and Merus NV Announce Collaboration

Gilead and Vir Biotechnology Establish Clinical Collaboration

Gilead and Vir Biotechnology Establish Clinical Collaboration

 

Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies

January 19, 2021 Download PDF

INDIANAPOLIS and UTRECHT, The Netherlands, Jan. 19, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a clinical-stage oncology company developing multi-specific antibodies, today announced a research collaboration and exclusive license agreement that will leverage Merus' proprietary Biclonics® platform along with the scientific and rational drug design expertise of Loxo Oncology at Lilly to research and develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies.


 For additional information, please visit Merus' website, www.merus.nl and https://twitter.com/MerusNV. 


 To learn more about Lilly, please visit us at www.lilly.com. 

https://www.lilly.com/


 View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-and-merus-nv-announce-collaboration-to-discover-novel-t-cell-re-directing-bispecific-antibodies-301210513.html 

 

Our Pipeline

The product candidates in the Merus pipeline are based on the Multiclonics® format (full length human IgG antibodies). Our strategy employs the unique attributes of our proprietary bispecific antibodies and our patented screening technologies to engage and harness the power of the immune system to target tumor cells.

https://merus.nl/pipeline/


https://seekingalpha.com/symbol/LLY


Our Pipeline The product candidates in the Merus pipeline are based on the Multiclonics® format (full length human IgG antibodies). Our strategy employs the unique attributes of our proprietary bispecific antibodies and our patented screening technologies to engage and harness the power of the immune system to target tumor cells.

tislelizumab

Gilead and Vir Biotechnology Establish Clinical Collaboration

Biogen, Genentech team up for a new neurodegenerative biotech

 

Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene

Back to News Archive

Jan 11, 2021

  • Agreement expands Novartis Oncology portfolio, adding late-stage PD-1 for monotherapy and potential proprietary PD-1 combinations, driving mid- and long-term growth
  • Novartis secures development and commercialization rights in North America, Europe, and Japan
  • Accelerates Novartis immuno-oncology combination strategy with multiple potential tislelizumab plus Novartis therapy combinations
  • Tislelizumab already approved for patients with classical Hodgkin’s lymphoma and metastatic urothelial carcinoma in China; 15 registration-enabling clinical trials under way in non-small cell lung cancer (NSCLC) and other solid tumors


Basel, January 11, 2021 — Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene, Ltd. in major markets outside of China, accelerating the potential for Novartis to enter the large and growing checkpoint inhibitor field. Tislelizumab is an anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells.


 

tislelizumab

 Tislelizumab is approved by the China National Medical Products Administration (NMPA) as a treatment for certain patients with classical Hodgkin’s lymphoma and metastatic urothelial carcinoma. In addition, BeiGene has filed three supplemental new drug applications for tislelizumab in China for first-line treatment of patients with advanced squamous NSCLC in combination with chemotherapy, first-line treatment of patients with advanced non-squamous NSCLC in combination with chemotherapy, and previously treated unresectable HCC. 


 Find out more at https://www.novartis.com. 


 

BeiGene Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab

Mon January 11, 2021 4:30 PM|Business Wire|About: BGNE

Novartis to co-develop and commercialize tislelizumab in North America, Japan, EU, and six other European countries

BeiGene (BGNE) to receive $650 million upfront payment and is eligible to receive up to $1.55 billion in potential regulatory and sales milestone payments plus royalties on product sales

BeiGene has the option to co-detail tislelizumab in North America

Both parties have freedom to conduct combination trials globally

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)-- BeiGene, Ltd.

https://seekingalpha.com/pr/18147035-beigene-announces-collaboration-novartis-to-develop-and-commercialize-anti-pdminus-1-antibody


https://seekingalpha.com/symbol/BGNE


https://seekingalpha.com/symbol/NVS


 

BeiGene, Novartis in Pact to develop tislelizumab for cancer settings

Jan. 11, 2021 4:47 PM ET BeiGene, Ltd. (BGNE)

By: Vandana Singh, SA News Editor

  • BeiGene (NASDAQ:BGNE) has announced a collaboration and license agreement with Novartis Pharma (NYSE:NVS) for the development, manufacture and commercialization of BeiGene’s anti-PD-1 antibody tislelizumab. https://seekingalpha.com/news/3650509-beigene-novartis-in-pact-to-develop-tislelizumab-for-cancer-settings

https://www.beigene.com/science-and-product-portfolio/pipeline/tislelizumab



Tislelizumab

Biogen, Genentech team up for a new neurodegenerative biotech

Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health

Biogen, Genentech team up for a new neurodegenerative biotech

 

Biogen, Genentech team up for a new neurodegenerative biotech

Jan. 11, 2021 12:40 PM ET Roche Holding AG (RHHBY) By: Vandana Singh, SA News Editor

  • Atalanta Therapeutics launches today with a Series A financing exclusively by F-Prime Capital.

 

Atalanta Therapeutics Launches With $110 Million to Pioneer RNAi Therapeutics for Neurodegenerative Diseases

Mon January 11, 2021 6:00 AM|Business Wire|About: BIIB, JNP

- Announces strategic collaborations with Biogen, Genentech to develop RNAi therapeutics for neurodegenerative diseases -

- Founders are world-leading experts in RNA interference, including Nobel (NLCI) laureate Craig Mello -

- Company has assembled a first-class management team of industry veterans helmed by CEO Alicia Secor -

BOSTON--(BUSINESS WIRE)-- Atalanta Therapeutics,

https://seekingalpha.com/pr/18145379-atalanta-therapeutics-launches-110-million-to-pioneer-rnai-therapeutics-for-neurodegenerative


 Preclinical research published in Nature Biotechnology has shown that branched siRNA can achieve unparalleled distribution in the CNS, including deep brain structures, and prolonged duration of effect. 


 For more information, visit www.atalantatx.com  


 F-Prime is headquartered in Cambridge, MA, with offices in London, UK and San Francisco, CA. For more information, please visit fprimecapital.com  

https://fprimecapital.com/


 View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005327/en/ 

 

Biogen, Genentech and F-Prime power new neurodegenerative biotech to $110M unveiling

by Nick Paul Taylor | Jan 11, 2021 9:15am 

https://www.fiercebiotech.com/biotech/biogen-genentech-and-f-prime-power-new-neurodegenerative-biotech-to-110m-unveiling


https://seekingalpha.com/symbol/BIIB


https://seekingalpha.com/symbol/RHHBY


https://www.atalantatx.com/

Our science & focus Our proprietary branched siRNA construct opens new frontiers in treating neurodegenerative diseases

Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health

Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health

Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health

 

BIOGEN TO LAUNCH PIONEERING STUDY TO DEVELOP DIGITAL BIOMARKERS OF COGNITIVE HEALTH USING APPLE WATCH AND IPHONE

January 11, 2021 at 7:30 AM EST

  • The study aims to identify digital biomarkers to help monitor cognitive performance and health including potentially detecting mild cognitive impairment, an early indicator of certain forms of dementia such as Alzheimer’s disease 
  • Cognitive health — the ability to think clearly, to learn and to remember — is an indicator of brain health and important to performing daily activities  

CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced a new virtual research study, in collaboration with Apple, to investigate the role Apple Watch and iPhone could play in monitoring cognitive performance and screening for decline in cognitive health including mild cognitive impairment (MCI). 


  information that may be important to investors on our website at www.biogen.com. 



 “Working in collaboration with Biogen, we hope this study can help the medical community better understand a person's cognitive performance by simply having them engage with their Apple Watch and iPhone,” said Jeff Williams, Apple’s chief operating officer. “We’re looking forward to learning about the impact our technology can have in delivering better health outcomes through improved detection of declining cognitive health.” 


https://www.biogen.com/en_us/home.html


 

Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone

Mon January 11, 2021 7:30 AM|GlobeNewswire|About: BIIB 

https://seekingalpha.com/pr/18145641-biogen-to-launch-pioneering-study-to-develop-digital-biomarkers-of-cognitive-health-using

 

Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health

Jan. 11, 2021 8:33 AM ET Biogen Inc. (BIIB) By: Vandana Singh, SA News Editor3 Comments

  • Biogen (NASDAQ:BIIB) 

https://seekingalpha.com/news/3650238-biogen-apple-collaborate-to-evaluate-device-role-in-digital-biomarkers-of-cognitive-health


https://www.biogen.com/en_us/pipeline.html


https://seekingalpha.com/symbol/BIIB



Pipeline

Chi-Med and Inmagene Announce Strategic Partnership

Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health

Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health

  11 Jan 2021

Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases

Hong Kong, Shanghai, San Diego & Florham Park, NJ: Monday, January 11, 2021: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Inmagene Biopharmaceuticals (“Inmagene”) today announce a strategic partnership to further develop four novel preclinical drug candidates discovered by Chi-Med for the potential treatment of multiple immunological diseases. Funded by Inmagene, the companies will work together to move the drug candidates towards investigational new drug (“IND”) submission. If successful, Inmagene will then move the drug candidates through global clinical development.


 For additional information about Inmagene Biopharmaceuticals, please visit www.inmagenebio.com. 


 

Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases

Sun January 10, 2021 8:00 PM|GlobeNewswire|About: HCM

HONG KONG, SHANGHAI, China, SAN DIEGO & FLORHAM PARK, N.J., Jan. 10, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (HCM) (“Chi-Med”) (Nasdaq/AIM: HCM) and Inmagene Biopharmaceuticals (“Inmagene”)

https://seekingalpha.com/pr/18145186-chi-med-and-inmagene-announce-strategic-partnership-to-develop-and-commercialize-portfolio-of


 

Chi-Med and Inmagene ink deal to develop candidates in immunological diseases

Jan. 11, 2021 12:54 AM ET Hutchison China MediTech Limited (HCM) By: Mamta Mayani, SA News Editor

  • Hutchison China MediTech (NASDAQ:HCM)

https://seekingalpha.com/news/3650130-chi-med-and-inmagene-ink-deal-to-develop-candidates-in-immunological-diseases


https://www.chi-med.com/

https://seekingalpha.com/symbol/HCM

PRODUCTS AND TECHNOLOGY

Sanofi to acquire Kymab, adding KY1005 to its pipeline

Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US

Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US

 January 11 2021

Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L

 

Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L

*Continues to build on Sanofi’s leading presence in immunology aligned with strategy to pursue best-in-class treatments in defined areas

PARIS and CAMBRIDGE, UK – January 11, 2021 – Sanofi and Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, have entered into an agreement under which Sanofi will acquire Kymab for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones.


 For more information on Kymab please see http://www.kymab.com. Kymab and IntelliSelect are trademarks of Kymab Limited. 


 

KY1005: Promising antibody for inflammatory disorders

In August 2020, Kymab announced that KY1005 met both primary endpoints in a Phase 2a trial studying moderate to severe atopic dermatitis patients whose disease is inadequately controlled with topical corticosteroids. KY1005 demonstrated a consistent treatment effect versus placebo across various key endpoints, including in the Eczema Area and Severity Index (EASI) and additional objective clinical measures.

“This acquisition aligns with our strategy of targeting fundamentally important disease pathways.  We believe that OX40L, a key immune regulator, has the potential to rebalance the immune system without suppressing it, providing a promising new approach to treating a range of immune-mediated diseases,” said John Reed, M.D. Ph.D., Global Head of Research & Development at Sanofi.

Kymab’s pipeline also includes the oncology asset KY1044, an ICOS agonist monoclonal antibody, currently in early Phase 1/2 development as monotherapy and in combination with an anti-PD-L1. The acquisition also provides Sanofi with access to new antibody technologies and research capabilities.


 

Sanofi to buy Kymab for $1.45B

Jan. 11, 2021 3:30 AM ETSanofi (SNY)By: Mamta Mayani, SA News Editor

  • Sanofi (NASDAQ:SNY) to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L.

https://seekingalpha.com/news/3650134-sanofi-to-buy-kymab-for-1_45b


https://seekingalpha.com/pr/18145263-sanofi-to-acquire-kymab-adding-ky1005-to-pipeline-human-monoclonal-antibody-targeting-key


https://www.sanofi.com/en

https://seekingalpha.com/symbol/SNY




Pipeline : We are utilizing our technology platforms to develop product candidates for immune disorders, cancer and haematological diseases.

Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US

Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US

Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US

 

Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US and Develop National Surveillance Infrastructure

With support from the Centers for Disease Control and Prevention (CDC), Illumina and Helix have already identified more than 50 cases of the new variant in the US

SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (Nasdaq: ILMN) and Helix today announced a collaboration to augment national surveillance infrastructure in the US to track the emergence and prevalence of novel strains of SARS-CoV-2 with support from the CDC. The combination of Illumina’s sequencing technology and expertise and Helix’s national COVID-19 testing footprint will significantly expand the country’s existing surveillance efforts to detect and characterize emerging variants of SARS-CoV-2.


 To learn more, visit www.illumina.com 

https://www.illumina.com/

https://seekingalpha.com/symbol/ILMN



 Learn more at www.helix.com. 


 View source version on businesswire.com: https://www.businesswire.com/news/home/20210105006007/en/ 


https://seekingalpha.com/pr/18140628-illumina-and-helix-collaborate-to-assess-prevalence-of-new-sars-covminus-2-uk-variant-b-1_1-7


 

Illumina gets CDC backing to track emergence of new COVID-19 strains

Jan. 09, 2021 1:55 PM ETIllumina, Inc. (ILMN)By: Dulan Lokuwithana, SA News Editor 

https://seekingalpha.com/news/3650113-illumina-gets-cdc-backing-to-track-emergence-of-new-covidminus-19-strains


https://www.helix.com/


Large-scale COVID-19 testing & screening Helix is expanding access to high-sensitivity molecular COVID-19 testing with next-day** turnaround time for health systems, employers, governments, and other organizations across the country.

Blacksmith Medicines launches with seed funding and a research collaboration with Lilly

Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

 

Blacksmith Medicines launches with seed funding and a research collaboration with Lilly

-Blacksmith Medicines, a spin-out of Forge Therapeutics, is pioneering a novel metalloenzyme chemistry platform to create new immuno-oncology and inflammation medicines –

– Research collaboration combines Blacksmith’s innovative chemistry platform with Lilly’s research and development expertise for novel human metalloenzyme-targeted medicines; total potential deal value up to approximately $300M –

SAN DIEGO, California, January 8, 2021 – Blacksmith Medicines, Inc. (Blacksmith), a biotechnology company focused on creating novel medicines for immuno-oncology and inflammatory diseases by targeting human metalloenzymes, announced today that it has secured seed funding and has entered into a research collaboration with Eli Lilly and Company (Lilly). Lilly joins existing Blacksmith investors Evotec A.G., MP Healthcare Partners, MagnaSci Ventures, and Alexandria Venture Investments. Blacksmith is a spin-out of Forge Therapeutics, a leading antibiotic discovery company discovering therapies to combat the rise of drug resistance.


 For further information, please visit the company’s website at www.BlacksmithMedicines.com  


 Blacksmith Medicines has developed a purpose-built platform focused on the discovery and development of small molecule inhibitors of metal-dependent enzymes. Over 30% of known enzymes are metalloenzymes, covering all major enzyme classes: oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. Metal ions, including magnesium, zinc, iron, manganese and copper are the essential ingredient in these metalloenzymes. 

https://blacksmithmedicines.com/technology/


https://blacksmithmedicines.com/

 

Eli Lilly collaborates with Blacksmith Medicines in a deal worth $300M

Jan. 08, 2021 8:43 AM ET Eli Lilly and Company (LLY) By: Dulan Lokuwithana, SA News Editor1 Comment 

https://seekingalpha.com/news/3649921-eli-lilly-collaborates-blacksmith-medicines-in-deal-worth-300m  

 

Blacksmith Medicines Launches With Seed Funding and a Research Collaboration With Lilly

-Blacksmith Medicines, a spin-out of Forge Therapeutics, is pioneering a novel metalloenzyme chemistry platform to create new immuno-oncology and inflammation medicines -

- Research collaboration combines Blacksmith's innovative chemistry platform with Lilly's research and development expertise for novel human metalloenzyme-targeted medicines; total potential deal value up to approximately $300M -

https://www.prnewswire.com/news-releases/blacksmith-medicines-launches-with-seed-funding-and-a-research-collaboration-with-lilly-301203230.html?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link


https://www.lilly.com/

https://seekingalpha.com/symbol/LLY



Blacksmith Medicines has developed a purpose-built platform focused on the discovery and development of small molecule inhibitors of metal-dependent enzymes. Over 30% of known enzymes are metalloenzymes, covering all major enzyme classes: oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. Metal ions, including magnesium, zinc, iron, manganese and copper are the essential ingredient in these metalloenzymes.

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

 

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

 Los Angeles, CA, USA, January 7, 2021 – ImaginAb Inc., a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. (NYSE: PFE) to supply 89Zr CD8 Immuno-PET agent, which can be used to image CD8 T cells in cancer patients. 


 For more information about ImaginAb’s pipeline and technology, visit www.imaginab.com. 


 

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

Thu January 7, 2021 3:00 AM|PR Newswire|About: PFE

LOS ANGELES, Jan. 7, 2021 /PRNewswire/ -- ImaginAb Inc., a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. (PFE) to supply 89Zr CD8 Immuno-PET agent, which can be used to image CD8 T cells in cancer patients.

https://seekingalpha.com/pr/18142445-imaginab-announces-license-and-supply-agreement-pfizer-for-cd8-immunopet-technology


 

View original content to download multimedia:http://www.prnewswire.com/news-releases/imaginab-announces-license-and-supply-agreement-with-pfizer-for-cd8-immunopet-technology-301202156.html


https://www.pfizer.com/

https://seekingalpha.com/symbol/PFE


 

ImaginAb inks supply deal with Pfizer for CD8 ImmunoPET technology in Cancer

Jan. 07, 2021 3:29 AM ETPfizer Inc. (PFE)By: Mamta Mayani, SA News Editor 

https://seekingalpha.com/news/3649479-imaginab-inks-supply-deal-pfizer-for-cd8-immunopet-technology-in-cancer



Optimizing combination therapies Visualizing immune response to inform the best immunotherapy treatment combinations.

PerkinElmer to Acquire Oxford Immunotec Global PLC

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

Roche renews partnership with Sysmex to deliver haematology testing solutions

Home / Investors / News releases News release details PerkinElmer to Acquire Oxford Immunotec Global PLC

PerkinElmer to Acquire Oxford Immunotec Global PLC

 January 7, 2021 at 7:00 AM ESTPDF Version

  • PerkinElmer to acquire Oxford Immunotec for USD 22.00 per share in cash
  • Transaction expected to be completed in the first half of 2021

WALTHAM, Mass. & LONDON--(BUSINESS WIRE)--Jan. 7, 2021-- PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) and Oxford Immunotec Global PLC (NASDAQ: OXFD) ("Oxford Immunotec" or the “Company”) are pleased to announce they have reached an agreement on terms under which PerkinElmer will acquire Oxford Immunotec (the “Acquisition”). It is intended that the Acquisition will be implemented by means of a U.K. High Court of Justice-sanctioned scheme of arrangement under Part 26 of the U.K. Companies Act 2006 between Oxford Immunotec and its shareholders (the “Scheme”).


 Additional information can be found at www.OxfordImmunotec.com. 

 

Product Pipeline

Our Focus

Our research and development activities focus on developing proprietary tests for the management of immune-regulated conditions. Our current focus is on four key areas: chronic infections, transplantation, autoimmune and inflammatory disease, and immune-oncology.

http://www.oxfordimmunotec.com/north-america/science/product-pipeline/


http://www.oxfordimmunotec.com/north-america/

 

PKI

PerkinElmer to acquire Oxford Immunotec for $591M
Today, 7:14 AM


https://www.perkinelmer.com/

https://seekingalpha.com/symbol/PKI


Product Pipeline Our Focus Our research and development activities focus on developing proprietary tests for the management of immune-regulated conditions. Our current focus is on four key areas: chronic infections, transplantation, autoimmune and inflammatory disease, and immune-oncology.

Roche renews partnership with Sysmex to deliver haematology testing solutions

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

Roche renews partnership with Sysmex to deliver haematology testing solutions

 

Roche renews partnership with Sysmex to deliver haematology testing solutions

  • This successful long-running partnership continues to evolve and bring haematology testing innovations to laboratories, globally
  • The new agreement aims to utilise the IT systems to lead to improved clinical decision making and customer experience
  • Blood disorders have a high impact, not only for patients but for society as a whole, accounting for a third of all central laboratory tests1

Basel, 25 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that, on 14 December, 2020, it signed a Global Business Partnership Agreement* (GBP) with Sysmex.


 About the Roche and Sysmex partnership
In 1999, Sysmex and Roche entered into a Distributorship Sales and Service Agreement (DSS), under which Roche distributed Sysmex hematology products and provided services in overseas markets. This mutually beneficial arrangement has since advanced as demands for haematology testing have evolved, with greater focus on automation of manual processes and streamlining workflow, expanding the utility of haematological parameters so as to support diagnosis, monitoring and treatment across disease areas, beyond routine testing. In 2018, Roche and Sysmex entered into a non-exclusive collaboration agreement to offer Total Laboratory Solutions (TLS). This means that customers who want to purchase products for clinical chemistry, immunochemistry, and hematology testing from one vendor, could do so seamlessly with Roche and Sysmex. 


 For more information, please visit www.roche.com. 

 

Roche extends partnership with Sysmex in haematology testing solutions

Jan. 25, 2021 3:02 AM ET Roche Holding AG (RHHBY) By: Mamta Mayani, SA News Editor

  • Roche (OTCQX:RHHBY) renews its Global Business Partnership Agreement (GBP) with Sysmex.

https://seekingalpha.com/news/3653750-roche-extends-partnership-with-sysmex-in-haematology-testing-solutions


https://www.sysmex.com/us/en/Pages/default.aspx


https://seekingalpha.com/symbol/RHHBY

Sysmex America is lighting the way to better health with diagnostic solutions that transform the future of healthcare and contribute to healthier lives.

BiotechVortex™

Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact

Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact

Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact

 

January 06, 2021

Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors

SANTA MONICA, Calif. & OXFORD, England & SAN JOSE, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), and Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-drug conjugate (ADC)-based therapies, announced that the companies have entered into a research collaboration to evaluate five novel targets for a number of hematologic and solid tumor indications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210106005129/en/


 For more information on Oxford BioTherapeutics, please visit www.oxfordbiotherapeutics.com. 


 For more information on Kite, please visit www.kitepharma.com. 


 For more information on Gilead Sciences, please visit the company’s website at www.gilead.com. 


 

Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors

Wed January 6, 2021 8:00 AM| Business Wire| About: GILD

SANTA MONICA, Calif. & OXFORD, England & SAN JOSE, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), and Oxford BioTherapeutics Ltd. (OBT)

https://seekingalpha.com/pr/18141148-kite-and-oxford-biotherapeutics-establish-cell-therapy-research-collaboration-in-blood


https://seekingalpha.com/symbol/GILD

 

Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact

Jan. 06, 2021 2:24 PM ET Gilead Sciences, Inc. (GILD)By: Vandana Singh, SA News Editor2 Comments

  • Kite, a Gilead Company (GILD +3.1%) and Oxford BioTherapeutics have entered into a research collaboration to evaluate five targets for a number of hematologic and solid tumor indications, using latter's OGAP target discovery platform.

https://seekingalpha.com/news/3649376-gileads-kite-oxford-biotherapeutics-ink-immuno-oncology-pact



OBT IO PIPELINE

Biogen inks deal for ophthalmic gene therapy development

Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact

Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact

 

ViGeneron signs global collaboration agreement for ophthalmic gene therapy development

Tue January 5, 2021 2:00 AM|GlobeNewswire|About: BIIB

  • Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target
  • The companies will use ViGeneron’s proprietary vgAAV technology to efficiently transduce target cells via intravitreal injections


MUNICH, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) -- ViGeneron GmbH, a gene therapy company, today announced a global collaboration and licensing agreement with Biogen Inc. (BIIB) (Nasdaq: BIIB, Cambridge, Mass., USA)


 For further information, please visit www.vigeneron.com. 


https://www.biogen.com/

https://seekingalpha.com/symbol/BIIB

 

Pipeline

https://www.biogen.com/en_us/pipeline.html


 

Biogen inks deal for ophthalmic gene therapy development

Jan. 05, 2021 2:39 AM ET Biogen Inc. (BIIB)

By: Mamta Mayani, SA News Editor4 Comments 

https://seekingalpha.com/news/3648630-biogen-inks-deal-for-ophthalmic-gene-therapy-development


Pipeline ViGeneron’s pipeline in gene therapy addresses ophthalmic diseases with high unmet medical need, including two lead programs in development for inherited retinal diseases where no approved treatment options are currently available.

Zai Lab and Cullinan Oncology Announce Strategic Collaboration

Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact

A2 Biotherapeutics Enters Into Collaboration Agreement With Merck

 

Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China

Mon December 28, 2020 7:30 AM|GlobeNewswire|About: ZLAB

- Zai Lab (ZLAB) to lead development and commercialization of CLN-081 in Greater China

- Cullinan will receive $20 million upfront, up to $211 million in future milestones, and royalties

- Zai Lab to join ongoing global trial for CLN-081

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited, an innovative commercial-stage biopharmaceutical company, and Cullinan Oncology  

 

About CLN-081

CLN-081 is an orally available, small-molecule, next-generation, irreversible EGFR inhibitor designed to selectively target cells expressing mutant EGFR variants. CLN-081 is currently in a Phase 1/2a dose escalation and expansion trial evaluating oral, twice-daily administration of various doses in patients with NSCLC harboring EGFR Ex20ins mutations who have had at least one prior treatment with platinum-based chemotherapy or another approved standard therapy. 


 For additional information about the company, please visit www.zailaboratory.com  


 For additional information, please visit www.cullinanoncology.com. 

https://seekingalpha.com/symbol/CGEM


https://www.cullinanoncology.com/


http://www.zailaboratory.com/

https://seekingalpha.com/symbol/ZLAB

 

Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China

December 28, 2020 at 7:30 AM ESTPDF Version

- Zai Lab to lead development and commercialization of CLN-081 in Greater China

- Cullinan will receive $20 million upfront, up to $211 million in future milestones, and royalties

- Zai Lab to join ongoing global trial for CLN-081

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and Cullinan Oncology, a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, today announced an exclusive license agreement for the development, manufacturing and commercialization of CLN-081 in Greater China.

https://zailab.gcs-web.com/news-releases/news-release-details/zai-lab-and-cullinan-oncology-announce-strategic-collaboration


https://seekingalpha.com/news/3647483-zai-lab-and-cullinan-oncology-ink-strategic-collaboration-and-license-agreement

We are advancing a portfolio of cancer therapies in various stages of preclinical and clinical development. Each candidate is structured as a separate company, a wholly owned subsidiary, with development managed centrally by the Cullinan Oncology team.

A2 Biotherapeutics Enters Into Collaboration Agreement With Merck

BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER

A2 Biotherapeutics Enters Into Collaboration Agreement With Merck

 

A2 Biotherapeutics Enters Into Collaboration Agreement With Merck To Develop Allogeneic Cell Therapy For Solid Tumor Cancers

Wed December 23, 2020 10:07 AM|PR NewswirePR Newswire

AGOURA HILLS, Calif., Dec. 23, 2020 /PRNewswire/ -- A2 Biotherapeutics (www.a2bio.com)


https://www.a2bio.com/our-science


 

For more information, visit www.a2bio.com. 

View original content to download multimedia:http://www.prnewswire.com/news-releases/a2-biotherapeutics-enters-into-collaboration-agreement-with-merck-to-develop-allogeneic-cell-therapy-for-solid-tumor-cancers-301197998.html

SOURCE A2 Biotherapeutics


https://seekingalpha.com/symbol/MRK


 

Merck, A2 Bio in development pact for allogeneic cell therapy candidates for cancer

Dec. 23, 2020 1:08 PM ETMerck & Co., Inc. (MRK)By: Vandana Singh, SA News Editor 

https://seekingalpha.com/news/3647078-merck-a2-bio-in-development-pact-for-allogeneic-cell-therapy-candidates-for-cancer



Our Science Accessing a new class of targets "Targets lost" in tumor cells

BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER

BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER

BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER

 BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER 

Dec 22, 2020 PDF Version

WHIPPANY, N.J. & SAN FRANCISCO--(BUSINESS WIRE)--Dec. 22, 2020--

 Bayer and Veracyte (Nasdaq: VCYT) today announced a new collaboration to advance the Precision Oncology Patient Identification Program in thyroid cancer. Through the program, Bayer will offer testing with Veracyte’s Afirma Xpression Atlas (XA) to identify underlying genomic drivers, including NTRK gene fusions, within patients’ tumors. The program will focus on patients with advanced or metastatic thyroid cancer that is radioactive iodine refractory (RAIR) who may potentially benefit from biomarker-driven therapies.


 For more information, go to www.bayer.us. 


 For more information, please visit www.veracyte.com

https://www.veracyte.com/  


 View source version on businesswire.com: https://www.businesswire.com/news/home/20201222005138/en/ 

 

Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer

Tue December 22, 2020 8:15 AM|Business Wire|About: VCYT

WHIPPANY, N.J. & SAN FRANCISCO--(BUSINESS WIRE)-- Bayer and Veracyte (VCYT) (Nasdaq: VCYT)

https://seekingalpha.com/pr/18131845-bayer-and-veracyte-announce-precision-oncology-collaboration-in-thyroid-cancer


https://seekingalpha.com/symbol/VCYT


https://seekingalpha.com/symbol/BAYZF

 

Veracyte and Bayer collaborate in precision oncology; 

Dec. 22, 2020 11:34 AM ET

Veracyte, Inc. (VCYT)By: Dulan Lokuwithana, 

SA News Editor 

https://seekingalpha.com/news/3646727-veracyte-and-bayer-collaborate-in-precision-oncology-shares-jumpplus-17



PIPELINE Reducing Unnecessary Surgeries and Informing Treatment Decisions in in cancer and other diseases

Aurinia inks deal for voclosporin in Europe and Japan with Otsuka Pharma

BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER

BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER

 

Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan

DOWNLOAD AS PDFDECEMBER 17, 2020

- Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and reimbursement milestone payments -

- Agreement includes royalties of up to 20 percent on net sales payable to Aurinia -

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of oral voclosporin for the treatment of Lupus Nephritis (LN) in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine.


 About Voclosporin
Voclosporin is a novel therapy in development for patients with LN, an inflammation of the kidney which is one of the most serious complications of the autoimmune disease SLE. If left untreated, LN can lead to irreversible kidney damage, kidney failure or even death. Through an extensive clinical program, voclosporin has demonstrated superiority to the standard-of-care for LN. 


 

Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan

Thu December 17, 2020 4:00 AM|Business Wire|About: AUPH

- Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and reimbursement milestone payments -

- Agreement includes royalties of up to 20 percent on net sales payable to Aurinia -

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (AUPH) 

https://seekingalpha.com/pr/18126413-aurinia-announces-collaboration-and-licensing-agreement-otsuka-pharmaceutical-co-ltd-for


 Learn more about Otsuka Pharmaceutical Company on its global website at https://www.otsuka.co.jp/en. 


 View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005216/en/ 


https://www.auriniapharma.com/


https://seekingalpha.com/symbol/AUPH


https://www.otsuka.co.jp/en/



Changing the course of autoimmune disease

Lilly Announces Agreement to Acquire Prevail Therapeutics

ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma

Lilly Announces Agreement to Acquire Prevail Therapeutics

 

Lilly Announces Agreement to Acquire Prevail Therapeutics

December 15, 2020Download PDFAcquisition will establish a gene therapy program at Lilly, anchored by Prevail's portfolio of neuroscience assets, and will broaden Lilly's commitment to use novel modalities to attempt to address otherwise fatal genetic forms of neurodegenerative disease

INDIANAPOLIS and NEW YORK, Dec. 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) today announced a definitive agreement for Lilly to acquire Prevail for $22.50 per share in cash (or an aggregate of approximately $880 million) payable at closing plus one non-tradable contingent value right ("CVR") worth up to $4.00 per share in cash (or an aggregate of approximately $160 million), for a total consideration of up to $26.50 per share in cash (or an aggregate of approximately $1.040 billion). The CVR is payable (subject to certain terms and conditions) upon the first regulatory approval of a product from Prevail's pipeline as set forth in more detail below. Prevail is a biotechnology company developing potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases.


 To learn more about Lilly, please visit us at www.lilly.com.  


https://www.prnewswire.com/news-releases/lilly-announces-agreement-to-acquire-prevail-therapeutics-301192753.html


https://www.prevailtherapeutics.com/our-science/#overview


https://seekingalpha.com/symbol/LLY


OUR SCIENCE We are pioneering the development of novel gene therapies that target the root genetic causes of Parkinson’s disease, frontotemporal dementia, Alzheimer’s disease, ALS, and other neurodegenerative disorders.

Veracyte broadens the collaboration with JNJ

ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma

Lilly Announces Agreement to Acquire Prevail Therapeutics

 VERACYTE ANNOUNCES EXPANSION OF COLLABORATION WITH THE LUNG CANCER INITIATIVE AT JOHNSON & JOHNSON<

 Dec 15, 2020 PDF Version

Collaboration to Focus on 9,000-Patient Clinical Trial for Development of Future Lung Cancer Early-Detection Tests

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 15, 2020-- Veracyte, Inc. (Nasdaq: VCYT) today announced it has expanded its long-term strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson1. The collaboration will include a focus on the NOBLE trial, a 9,000-patient, prospective, multicenter clinical study designed to distinguish genomic and other differences in lung cancer development and progression among patients with lung nodules detected by CT imaging.

 

Veracyte broadens the collaboration with JNJ in early cancer detection

Dec. 15, 2020 9:49 AM ET Veracyte, Inc. (VCYT)By: Dulan Lokuwithana, SA News Editor 

https://seekingalpha.com/news/3644460-veracyte-broadens-collaboration-jnj-in-early-cancer-dete


https://seekingalpha.com/symbol/VCYT


https://seekingalpha.com/symbol/JNJ


 For more information, please visit www.veracyte.com 


 View source version on businesswire.com: https://www.businesswire.com/news/home/20201215005345/en/ 

 

PIPELINE

Reducing Unnecessary Surgeries and Informing Treatment Decisions in in cancer and other disease

https://www.veracyte.com/our-products/pipeline




PIPELINE Reducing Unnecessary Surgeries and Informing Treatment Decisions in in cancer and other disease

ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma

ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma

ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma

 

ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater China and Singapore

DECEMBER, 14, 2020

- Hillhouse-backed Overland Pharmaceuticals to initially contribute $50 million to fund operations and development

LAUSANNE, Switzerland & SHANGHAI & BOSTON--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE:ADCT) and Overland Pharmaceuticals, a fully integrated biopharmaceutical company backed by Hillhouse Capital, today announced that they have jointly formed a new company, Overland ADCT BioPharma (CY) Limited, to develop and commercialize four of ADC Therapeutics’ antibody drug conjugate (ADC) product candidates for difficult-to-treat hematologic and solid tumors – loncastuximab tesirine (Lonca), ADCT-601, ADCT-602 and ADCT-901 – in greater China and Singapore. Overland Pharmaceuticals has invested $50 million in Overland ADCT BioPharma to fund operations, including development plans for approval of Lonca for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in the licensed territory.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201214005195/en/


 For more information, please visit https://adctherapeutics.com/  

https://seekingalpha.com/symbol/ADCT


https://www.overlandpharma.com/

 

OUR PIPELINE

https://www.overlandpharma.com/our-pipeline/



https://seekingalpha.com/pr/18120747-adc-therapeutics-and-overland-pharmaceuticals-announce-formation-of-overland-adct-biopharma

OUR PIPELINE

AstraZeneca buying Alexion in $39B cash and stock deal

Thermo Fisher Scientific Expands Global Footprint Drug Product Development& Commercial Manufacturing

ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma


AstraZeneca Agrees to Buy Alexion for $39 Billion

The deal would bolster the British drug giant’s footprint in rare diseases 

By Jenny Strasburg   and Joseph Walker

Updated Dec. 12, 2020 12:27 pm ET 

 LONDON— AstraZeneca AZN 0.71% PLC said it agreed to buy Boston-based Alexion Pharmaceuticals Inc. ALXN 1.78% for $39 billion in cash and stock, a move that would bolster the British drug giant’s footprint in rare diseases. 

 

AstraZeneca to acquire Alexion bulking up rare disease portfolio

Dec. 12, 2020 11:52 AM ET

AstraZeneca PLC (AZN) By: Dulan Lokuwithana, SA News Editor 

https://seekingalpha.com/news/3643893-astrazeneca-to-acquire-alexion-bulking-up-rare-disease-portfolio


https://seekingalpha.com/symbol/AZN


https://seekingalpha.com/symbol/ALXN


https://alexion.com/our-research/pipeline


 Accelerating AstraZeneca’s strategic and financial development AstraZeneca to acquire Alexion This webinar and conference call for investors and analysts is being recorded 12 December 2020 

https://www.astrazeneca.com/content/dam/az/PDF/2020/20201212_Call_Alxn_Cmb_prsn.pdf?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link


PIPELINE Advancing Our Pipeline Every Day

Gilead Sciences to Acquire MYR GmbH Thu December 10, 2020 8:00 AM|Business Wire|About: GILD

Thermo Fisher Scientific Expands Global Footprint Drug Product Development& Commercial Manufacturing

Thermo Fisher Scientific Expands Global Footprint Drug Product Development& Commercial Manufacturing

 

December 10, 2020

Gilead Sciences to Acquire MYR GmbH

– Gilead to Acquire Hepcludex™, a First-in-Class Entry Inhibitor, for Treatment of Chronic Hepatitis Delta Virus (HDV), Adding Immediate Revenue After Closing of Transaction –

– Hepcludex Was Conditionally Approved in Europe in July 2020 Based on Phase 2 Data and Submission for Accelerated Approval in United States is Anticipated in Second Half of 2021 –

– Acquisition Builds on Gilead’s Strength as a Global Leader in Virology and Liver Diseases with Addition of First Marketed Product for Treatment of HDV –

FOSTER CITY, Calif. & BAD HOMBURG, Germany--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and MYR GmbH, a German biotechnology company f


 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005315/en/


 Additional information about the agreement can be found at Gilead’s Investors page at http://investors.gilead.com. 


 For more information on MYR, please visit the company's website at www.myr-pharma.com. 


 For more information on Gilead Sciences, please visit the company’s website at www.gilead.com. 


 

Gilead Sciences to Acquire MYR GmbH

Thu December 10, 2020 8:00 AM|Business Wire|About: GILD 

https://seekingalpha.com/pr/18117705-gilead-sciences-to-acquire-myr-gmbh


https://seekingalpha.com/symbol/GILD


MYR Pharmaceuticals is a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis B (HBV) and D (HDV) infections. The company’s lead compound Bulevirtide (formerly known as Myrcludex B) is a first-in-class entry inhibitor for treatment of chronic HBV and HDV and is currently in a Phase 3 study in the indication of chronic HDV.

Thermo Fisher Scientific Expands Global Footprint Drug Product Development& Commercial Manufacturing

Thermo Fisher Scientific Expands Global Footprint Drug Product Development& Commercial Manufacturing

Thermo Fisher Scientific Expands Global Footprint Drug Product Development& Commercial Manufacturing

 Thermo Fisher Scientific Further Expands Global Footprint for Drug Product Development and Commercial Manufacturing

WALTHAM, Mass., Dec. 9, 2020 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced it will further expand its footprint in North America and Europe for sterile drug product development and commercial manufacturing of critical medicines, therapies and vaccines.


https://corporate.thermofisher.com/en/home.html


https://www.thermofisher.com/us/en/home.html


 

Thermo Fisher Scientific Further Expands Global Footprint for Drug Product Development and Commercial Manufacturing

Wed December 9, 2020 8:00 AM|PR Newswire

WALTHAM, Mass., Dec. 9, 2020 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced it will further expand its footprint in North America and Europe for sterile drug product development and commercial manufacturing of critical medicines, therapies and vaccines.

https://seekingalpha.com/pr/18115833-thermo-fisher-scientific-expands-global-footprint-for-drug-product-development-and-commercial


 For more information, please visit www.thermofisher.com. 

https://seekingalpha.com/symbol/TMO


 

Thermo Fisher Scientific and Innoforce Partner to Establish Biologics and Steriles Drug Manufacturing Facility in China

Fri November 6, 2020 6:00 AM|PR Newswire|About: TMO 

https://seekingalpha.com/pr/18074732-thermo-fisher-scientific-and-innoforce-partner-to-establish-biologics-and-steriles-drug


  For more information, please visit www.innoforcepharma.com. 



Thermo Fisher Scientific and Innoforce Partner to Establish Biologics and Steriles Drug Manufacturing Facility in China Fri November 6, 2020 6:00 AM|PR Newswire|About: TMO PR Newswire WALTHAM, Mass. and SHANGHAI, Nov. 6, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (TMO), the world leader in serving science, and Innoforce, a bioinnovation-enabling company, today announced they have signed a joint venture agreement to establish a new pharma services facility in Hangzhou, China, for integrated biologics and steriles drug development and manufacturing. The new facility is expected to be completed in 2022.

BiotechVortex™

中国生物制药向科兴中维注资5.15亿美元,持股15.03% 2020-12-7

Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel

Y-mAbs, inks distribution pact with Takeda for nerve cell cancer meds, Danyelza & omburtamab

 Companies

Sino Biopharm secures room for future growth with US$515 million investment in Sinovac’s Covid-19 vaccine unit

Beijing-based generic drug maker buys 15 per cent stake in Sinovac Life Sciences, a unit of Nasdaq-listed pharmaceutical firm Sinovac Biotech
Deal comes ahead of major announcement from China to launch 600 million doses of Covid-19 vaccines for use this year

Eric Ng Published: 3:18pm, 7 Dec, 2020


http://www.sinobiopharm.com/index.html#/


http://www.sinovac.com/


 

中国生物制药向科兴中维注资5.15亿美元,持股15.03%

2020-12-7

2020年12月7日,中国生物制药发布公告称,连同其附属公司的全资附属公司香港俊领有限公司就以5.15亿美元向北京科兴中维生物技术有限公司(简称科兴中维)出资订立协议。于出资完成后,中国生物制药将于科兴中维的注册资本中拥有15.03%权益。科兴中维将于中国生物制药的财务报表中入账列为联营公司。

http://www.sinobiopharm.com/index.html#/news/newsdeatil?id=2630


 

Y-mAbs, inks distribution pact with Takeda for nerve cell cancer meds, Danyelza & omburtamab

Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel

Y-mAbs, inks distribution pact with Takeda for nerve cell cancer meds, Danyelza & omburtamab


  • Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel

Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel

Dec 04, 2020PDF Version

NEW YORK and PETACH TIKVA, Israel, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB)

 

Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel

NEW YORK and PETACH TIKVA, Israel, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) (the “Company” or “Y-mAbs”) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment ofRead moreDec 04, 2020 

 

Y-mAbs, inks distribution pact with Takeda for nerve cell cancer meds, Danyelza & omburtamab

Dec. 04, 2020 9:30 AM ETY-mAbs Therapeutics, Inc. (YMAB)By: Vandana Singh, SA News Editor 

https://seekingalpha.com/news/3641765-y-mabs-inks-distribution-pact-takeda-for-nerve-cell-cancer-meds-danyelza-omburtamab


https://seekingalpha.com/symbol/YMAB


https://www.takeda.com/en-us

https://seekingalpha.com/symbol/TAK

 

About the Y-mAbs development pipeline of therapies

https://ymabs.com/research-development/pipeline/



About the Y-mAbs development pipeline of therapies

Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel

Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel

Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel

 

Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology

Thu December 3, 2020 3:00 AM|PR Newswire

  • Merck KGaA, Darmstadt, Germany and Artios will conduct collaborative research and Merck KGaA, Darmstadt, Germany shall have the right to opt into exclusive development and commercialization of compounds on up to 8 targets
  • Artios to receive US$30 million in up-front and near-term payments, plus double-digit option fees and up to US$860 million total milestones per target 
  • Collaboration to leverage significant expertise and R&D resources of Merck KGaA, Darmstadt, Germany in the field of DNA Damage Response to identify and develop precision oncology medicines targeting nucleases 

DARMSTADT, Germany, CAMBRIDGE, UK and NEW YORK, Dec. 3, 2020 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany, a leading science and technology company and Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, today announced a global three year strategic research collaboration to discover and develop multiple precision oncology drugs.



 www.artiospharma.com 


 View original content:http://www.prnewswire.com/news-releases/merck-kgaa-darmstadt-germany-and-artios-pharma-announce-a-global-strategic-collaboration-on-novel-dna-damage-response-targets-in-oncology-301185247.html 


https://seekingalpha.com/symbol/MKGAY


https://www.artiospharma.com/science/#pipeline


https://www.emdgroup.com/en

 

Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology

December 3, 2020
 

Our pipeline Working with its collaborators, Artios is drugging novel protein classes across a range of DDR pathways. Artios has in-licensed two lead programmes from Cancer Research Technology, which target proteins that control key aspects of DNA repair and other cellular processes.

Bioengineered Antibody-Toxin Fusion Proteins- FastPharming® System

Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extract

Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel

 

iBio Selected to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins

Tue December 1, 2020 4:30 PM | Globe Newswire | About: IBIO

BRYAN, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (IBIO) (NYSEA:IBIO) 

 

Bioengineered Antibody-Toxin Fusion Proteins

 

New line of attack against cancer

atbodies are differentiated by both their unique composition and novel mechanism of action, providing a new class of biologic as an innovative therapeutic solution for hard-to-treat and refractory cancer.

https://www.atbtherapeutics.com/atbody


 under a Master Services Agreement with Belgium-based ATB Therapeutics (“atbtherapeutics”) to produce its bioengineered antibody-toxin fusion proteins using iBio’s FastPharming® System. 


 FastPharming® System 

 

FastPharming®

Advantages of Plant Based Protein Production

https://www.ibioinc.com/technology/fastpharming


 For more information, visit www.ibioinc.com. 


https://seekingalpha.com/symbol/IBIO


 For more information, visit www.atbtherapeutics.com. 



iBio Selected to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins Download as PDFDECEMBER 01, 2020 4:30PM EST BRYAN, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO

BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years

Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extract

Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extract

 

BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years

Wed December 2, 2020 7:00 AM|PR Newswire|About: BDX

- Investment includes new manufacturing facility in Europe

FRANKLIN LAKES, N.J., Dec. 2, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company (BDX)) (NYSE: BDX)


 The new manufacturing facility in Europe is expected to be operational by the end of 2023. 


 For more information on BD, please visit bd.com. 



 View original content to download multimedia:http://www.prnewswire.com/news-releases/bd-to-invest-1-2-billion-in-pre-fillable-syringe-manufacturing-capacity-over-next-four-years-301183330.html 


 

12/02/2020

BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years


https://seekingalpha.com/news/3640859-becton-dickinson-to-invest-1_2b-in-pre-fillable-syringe-manufacturing-capacity


https://seekingalpha.com/symbol/BDX


BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years PDF Version Investment includes new manufacturing facility in Europe FRANKLIN LAKES, N.J., Dec. 2, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX),

Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extract

Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extract

Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extract

 

Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extracts in Germany

Wed December 2, 2020 8:00 AM|Business Wire|About: TLRY

BERLIN & FRANKFURT, Germany--(BUSINESS WIRE)-- Tilray, Inc. (TLRY) (“Tilray” or the “Company”) (Nasdaq: TLRY), a leading company in the manufacture, research and distribution of medical cannabis, announced that it has entered into a co-promotion agreement with Hormosan for its full-spectrum cannabis extracts in Germany effective 1 January 2021.


 "With Hormosan we have gained a partner that has excellent expertise and contacts in the field of pain therapy and neurology and will thus significantly increase the visibility of Tilray's full-spectrum cannabis extracts in the future," explains Sascha Mielcarek, Managing Director Europe at Tilray. “This will give physicians and patients even better access to our medical cannabis extracts while supporting our goal of contributing to improved care for patients with medical cannabis." 

https://www.hormosan.com/


 View source version on businesswire.com: https://www.businesswire.com/news/home/20201202005128/en/ 

 

HORMOSANSeltene Erkrankungen
in der Neurologie

https://www.hormosan.com/seltene_erkrankungen.html 

 

Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extracts in Germany

BERLIN & FRANKFURT, Germany --(BUSINESS WIRE)--Dec. 2, 2020-- Tilray, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a leading company in the manufacture, research and distribution of medical cannabis, announced that it has entered into a co-promotion agreement with Hormosan for its full-spectrum
December 2, 2020


https://www.tilray.com/

https://seekingalpha.com/symbol/TLRY


https://ir.tilray.com/news-releases/news-release-details/tilray-inc-and-hormosan-sign-cooperation-agreement-promotion


Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extracts in Germany December 2, 2020 at 8:00 AM EST PDF Version BERLIN & FRANKFURT, Germany--(BUSINESS WIRE)--Dec. 2, 2020-- Tilray, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a leading company in the manufacture, research and distribution of medical cannabis, announced that it has entered into a co-promotion agreement with Hormosan for its full-spectrum cannabis extracts in Germany effective 1 January 2021.

Frontier Medicines and AbbVie Establish Global Partnership to Discover and Develop Novel Therapies

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Br

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Br

 

Frontier Medicines and AbbVie Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets

Wed December 2, 2020 8:00 AM|PR Newswire|About: ABBV

- Frontier eligible to receive up to $100 million in upfront and milestone payments within the first 12 months of collaboration

PR Newswire

NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Dec. 2, 2020 /PRNewswire/ -- AbbVie (ABBV), a research-based global biopharmaceutical company, and Frontier Medicines, Corp.,



 For more information, visit www.frontiermeds.com  


 For more information about AbbVie, please visit us at www.abbvie.com. 


https://seekingalpha.com/symbol/ABBV


 

Science

https://frontiermeds.com/science/#chemoproteomics


 Dec 02, 2020

AbbVie and Frontier Medicines Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets

NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Dec. 2, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Frontier Medicines, Corp., a precision medicine company drugging challenging protein targets to develop breakthrough medicines that change the course of human diseases, today announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative small molecule therapeutics against high-interest, difficult-to-drug protein targets.


December 2, 2020 AbbVie and Frontier Medicines Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets Sign Up for Alerts Print - Multi-year, multi-program R&D partnership to deliver innovative treatment options across cancer and immunological diseases - Frontier eligible to receive up to $100 million in upfront and milestone payments within the first 12 months of collaboration NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Dec. 2, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV)

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Br

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Br

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Br

 

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders

Fri November 27, 2020 7:30 AM|Business Wire|About: BIIB, SAGE

  • Biogen and Sage enter into an agreement to jointly develop and commercialize zuranolone and SAGE-324 in the U.S.
  • Biogen to receive exclusive license to develop and commercialize zuranolone and SAGE-324 outside of the U.S., excluding rights to zuranolone in Japan, Taiwan and South Korea
  • Sage Therapeutics (SAGE) to receive $1.525 billion in cash comprised of an upfront payment of $875 million and a $650 million equity investment as well as potential milestone payments, profit sharing and royalties
  • Sage to host conference call Monday, November 30 at 8:00 a.m. ET
  • Biogen to host conference call Monday, November 30 at 9:00 a.m. ET

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (BIIB) (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that they have executed a global collaboration and license agreement to jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), postpartum depression (PPD) and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201127005340/en/


 Zuranolone is a next-generation positive allosteric modulator of the gamma-aminobutyric acid (GABAA) receptor. The GABAA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS), and contributes significantly to regulating CNS function. This mechanism of action is a novel approach that may enable a new class of antidepressants. 


 We routinely post information that may be important to investors on our website at www.biogen.com. 

https://seekingalpha.com/symbol/BIIB


 For more information, please visit www.sagerx.com. 

https://seekingalpha.com/symbol/SAGE

https://www.sagerx.com/programs-research/pipeline/



 

November 27, 2020

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders



Pipeline Advancing a Leading Brain Health Portfolio Our differentiated approach to drug discovery and development has allowed us to create a broad portfolio of fully-owned product candidates with the potential for development in a wide range of psychiatric, neurological and related central nervous system (CNS) disorders.

BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Br

BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel

 

BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel Immunotherapies

Wed November 25, 2020 7:45 AM|GlobeNewswire|About: BNTX

  • Long-term collaboration underpins BioNTech’s strategy to leverage Artificial Intelligence (AI) and Machine Learning (ML) technologies to support the discovery and development of novel immunotherapies based on InstaDeep’s DeepChainTM technology platform
  • BioNTech (NTGN) and InstaDeep to establish a joint AI Innovation Lab to advance a portfolio of enterprise-wide digital initiatives in the areas of drug discovery and design, protein engineering, and operations

MAINZ, Germany and LONDON, United Kingdom, November 25, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech”) and InstaDeep Ltd

 For more information, please visit www.BioNTech.de. 

 To learn more, please visit www.instadeep.com. 

https://seekingalpha.com/symbol/BNTX

Research

InstaDeep’s in-house research team contributes to the latest advancements in AI – from the fundamentals of machine learning to robotics and deep reinforcement learning. Our published research has been presented at world-leading conferences such as NeurIPS 2018.

https://www.instadeep.com/research/

25 November 2020

BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation ..

OPEN 

Pipeline

Schrödinger Announces a Collaboration with Bristol Myers Squibb

Schrödinger Announces a Collaboration with Bristol Myers Squibb

BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel

 

Schrödinger Announces a Multi-Target Drug Discovery, Development, and Commercialization Collaboration with Bristol Myers Squibb

Mon November 23, 2020 6:30 AM|Business Wire|About: BMY, SDGR

Schrödinger to receive $55 million upfront; eligible to receive up to $2.7 billion in milestone payments plus royalties

NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced a discovery collaboration with Bristol Myers Squibb Company (NYSE: BMY) to discover, develop, and commercialize therapeutics in multiple disease areas.


 To learn more, visit www.schrodinger.com  


 View source version on businesswire.com: https://www.businesswire.com/news/home/20201123005663/en/ 


https://seekingalpha.com/symbol/SDGR


https://seekingalpha.com/symbol/BMY


 

Schrödinger inks multi-target drug discovery deal with Bristol-Myers Squibb

https://seekingalpha.com/news/3638576-schrodinger-inks-multi-target-drug-discovery-deal-bristol-myers-squibb


https://www.schrodinger.com/pipeline




OUR VISION IN ACTION Our platform enables discovery of high-quality, novel molecules more rapidly, at lower cost

OneOncology Partners with Genentech

Schrödinger Announces a Collaboration with Bristol Myers Squibb

OneOncology Partners with Genentech

 

OneOncology Partners with Genentech to Bring Personalized Cancer Research to Patients at Community Oncology Sites

Mon November 23, 2020 6:15 AM|PR Newswire|About: RHHBY

MyTACTIC Precision Basket Trial is Scheduled to Launch in December 2020 at Community Oncology Centers Including OneOncology

PR Newswire

NASHVILLE, Tenn., Nov. 23, 2020 /PRNewswire/ -- OneOncology, the national partnership of independent oncology practices, and Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)


 Genentech's new clinical trial -- Targeting Actionable Mutation Study in Cancer (MyTACTIC) -- aims to match patient populations with a targetable genomic alteration to a specific investigational agent. 


 View original content to download multimedia:http://www.prnewswire.com/news-releases/oneoncology-partners-with-genentech-to-bring-personalized-cancer-research-to-patients-at-community-oncology-sites-301178283.html 


 About OneOncology: 
OneOncology is a national partnership of independent, community oncology practices working together to improve the lives of everyone living with cancer through a physician-led, data-driven, technology-powered and patient-centric model. OneOncology is comprised of leading community oncology practices representing over 475 providers practicing at nearly 175 sites of care across the United States. 

https://www.oneoncology.com/


https://www.gene.com/media


https://www.roche.com/


https://seekingalpha.com/symbol/RHHBY




OneR is a national site management organization that brings operational expertise and centralized services to efficiently deliver multi-center clinical research across our growing network of community oncology practices.

Merck to Acquire OncoImmune

Schrödinger Announces a Collaboration with Bristol Myers Squibb

OneOncology Partners with Genentech

 

Merck to Acquire OncoImmune

Save

November 23, 2020 6:45 am EST

Acquisition adds to Merck’s suite of clinical programs in response to SARS-CoV-2/COVID-19

Merck will accelerate development of CD24Fc, a candidate for the treatment of patients with severe and critical COVID-19

KENILWORTH, N.J., & ROCKVILLE, Md.--(BUSINESS WIRE)-- Merck (NYSE: MRK)


 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201123005593/en/ 


 

Merck adds to suite of COVID-19 clinical programs through OncoImmune acquistion

Nov. 23, 2020 6:54 AM ETMerck & Co., Inc. (MRK)By: Gaurav Batavia, SA News Editor 

https://seekingalpha.com/news/3638577-merck-adds-to-suite-of-covidminus-19-clinical-programs-through-oncoimmune-acquistion


https://seekingalpha.com/symbol/MRK


  Visit www.oncoimmune.com. 



OncoImmune’s founders have identified a novel pathway that is a checkpoint for the development of a number of disease indications. Our lead molecule, CD24Fc, targets this pathway and efficiently modulate the immune response in animal models of GVHD, multiple sclerosis and rheumatoid arthritis. We have completed phase II clinical trial for GVHD and is launching a pivotal phase III clinical trial for the indication.

BiotechVortex™

QIAGEN Collaborates with BioNTech on Companion Diagnostics Development

Lilly & Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

Lilly & Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

 

QIAGEN Collaborates with BioNTech on Companion Diagnostics Development for HPV-associated Squamous Cell Carcinoma of the Head and Neck

Wed November 18, 2020 4:05 PM|Business Wire|About: BNTX, QGEN

  • QIAGEN and BioNTech (NTGN) to develop tissue-based therascreen® test covering a panel of HPV genotypes, paired with investigational treatment BNT113, to identify patients whose cancers are caused by HPV infections
  • QIAGEN to pursue global regulatory approvals, including Premarket Approval from FDA for companion diagnostics
  • Collaboration leverages QIAGEN´s global reach and market-leading position in companion diagnostics and HPV testing

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)-- QIAGEN N.V. (QGEN)


 View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005908/en/ 


https://www.qiagen.com/us/

https://seekingalpha.com/symbol/QGEN


https://biontech.de/

https://seekingalpha.com/symbol/BNTX





NOV 18 2020 QIAGEN collaborates with BioNTech on companion diagnostics development for HPV-associated squamous cell carcinoma of the head and neck • QIAGEN and BioNTech to develop tissue-based therascreen® test covering a panel of HPV genotypes, paired with investigational treatment BNT113, to identify patients whose cancers are caused by HPV infections • QIAGEN to pursue global regulatory approvals, including Premarket Approval from FDA for companion diagnostics • Collaboration leverages QIAGEN´s global reach and market-leading position in companion diagnostics and HPV testing Hilden, Germany and Germantown, Maryland, November 18, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a strategic collaboration with BioNTech SE (Nasdaq: BNTX)

Lilly & Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

Lilly & Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

Lilly & Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

 

Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

Thu November 19, 2020 6:45 AM|PR Newswire|About: LLY

BURGDORF, Switzerland and INDIANAPOLIS, Nov. 19, 2020 /PRNewswire/ -- Eli Lilly and Company (LLY) and Ypsomed (YPHDF) (SWX: YPSN)  For the latest updates, visit http://www.lillydiabetes.com/  


 Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes 

https://www.ypsomed.com/en/media/details/lilly-and-ypsomed-collaborate-to-advance-an-automated-insulin-delivery-system-for-people-with-diabetes.html


 Additional information is available under www.ypsomed.com. 


 View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-and-ypsomed-collaborate-to-advance-an-automated-insulin-delivery-system-for-people-with-diabetes-301176401.html 


 
Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

November 19, 2020

Tags |  Product

BURGDORF, Switzerland and INDIANAPOLIS , Nov. 19, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) and Ypsomed (SWX: YPSN) announced today a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly 's connected diabetes solutions.


https://seekingalpha.com/symbol/LLY



Injection systems for self-medication

Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in G

Lilly & Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in G

 

Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in Greater China

Thu November 19, 2020 7:00 AM|Business Wire|About: PFE

NEW YORK & SHANGHAI & PRINCETON, N.J.--(BUSINESS WIRE)-- Pfizer, Inc. (PFE) and LianBio 


 For more information, please visit lianbio.com. 


 We routinely post information that may be important to investors on our website at www.pfizer.com.cn. 


 View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005290/en/ 


https://www.lianbio.com/pipeline/


https://seekingalpha.com/symbol/PFE


https://seekingalpha.com/news/3637861-pfizer-teams-up-lianbio-for-development-of-novel-therapeutics-in-greater-china



LianBio collaborates with world class partners, selecting programs with strong scientific basis and clinical data resulting in a broad and validated late-stage pipeline with first-in-class profile as well as other high potential candidates

Ultragenyx to build gene therapy manufacturing facility

Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders

Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in G

 

Ultragenyx Announces Plans to Build Large-scale Gene Therapy Manufacturing Facility to Support Pipeline of Therapies for Rare Diseases

Mon November 9, 2020 8:05 AM|GlobeNewswire|About: RARE

State-of-the-art facility to be located in Bedford, Massachusetts

NOVATO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc.  (RARE)

 

Ultragenyx to build gene therapy manufacturing facility

 Nov. 9, 2020 9:27 AM ET|About: Ultragenyx Pharmaceutical... (RARE)|By: Vandana Singh, SA News Editor  


 For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com. 


https://seekingalpha.com/symbol/RARE



 Nov 9, 2020Ultragenyx Announces Plans to Build Large-scale Gene Therapy Manufacturing Facility to Support Pipeline of Therapies for Rare Diseases 

Ultragenyx is a biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no typically no approved therapies treating the underlying disease.

Novartis buys Vedere Bio for $280M

Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders

Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders

 

Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company

Thu October 29, 2020 2:15 AM|PR Newswire

$150 million upfront with the remainder in early regulatory and clinical milestones for a total of $280 million

Newly formed Vedere Bio II will leverage an ocular gene therapy toolbox to develop a new pipeline of novel vision restoration and vision preservation therapies

PR Newswire

CAMBRIDGE, Mass., Oct. 29, 2020 /PRNewswire/ -- Vedere Bio, Inc. (Vedere Bio), a stealth-stage company focused on advancing photoreceptor-protein-based optogenetic therapies that are delivered to the retina intravitreally to restore functional vision, announced today that it has been acquired by Novartis.

 

Novartis buys Vedere Bio for $280M

https://seekingalpha.com/news/3627953-novartis-buys-vedere-bio-for-280m

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/novartis-acquires-vedere-bio-a-novel-optogenetics-aav-gene-therapy-company-301162269.html

SOURCE Vedere Bio, Inc.


https://seekingalpha.com/symbol/NVShttps://seekingalpha.com/symbol/NVS


https://www.vederebio.com/

 

Novartis acquires Vedere Bio, adding novel optogenetic gene therapy technology for treating blindness

Oct 29, 2020

  • Acquisition expands the Novartis footprint in ophthalmology and enhances the company’s position as an AAV-based gene therapy powerhouse.

  • Novartis gains two pre-clinical optogenetic AAV gene therapy programs and novel delivery technology for treating inherited retinal dystrophies and geographic atrophy.

  • Inherited retinal dystrophies, including advanced retinitis pigmentosa, affect greater than 2 million patients worldwide, and geographic atrophy affects approximately 5 million patients worldwide.

Basel, October 29, 2020

https://www.novartis.com/news/media-releases/novartis-acquires-vedere-bio-adding-novel-optogenetic-gene-therapy-technology-treating-blindness


Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company Acquisition of Vedere Bio includes lead preclinical intravitreally-injected AAV gene therapy programs focused on pan-genotypic vision restoration in patients with photoreceptor-based vision loss $150 million upfront with the remainder in early regulatory and clinical milestones for a total of $280 million Newly formed Vedere Bio II will leverage an ocular gene therapy toolbox to develop a new pipeline of novel vision restoration and vision preservation therapies CAMBRIDGE, Mass., October 29, 2020 – Vedere Bio, Inc. (Vedere Bio), a stealth-stage company focused on advancing photoreceptor-protein-based optogenetic therapies that are delivered to the retina intravitreally to restore functional vision, announced today that it has been acquired by Novartis. Shareholders in Vedere Bio received $150 million upfront and will be eligible for up to $130 million in milestone payments, for a total of $280 million.

Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders

Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders

Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders

 

insitro Announces Five-Year Discovery Collaboration with Bristol Myers Squibb to Discover and Develop Novel Treatments for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Wed October 28, 2020 7:00 AM|Business Wire|About: BMY

insitro to Receive $50 Million in Upfront Cash with Total Potential Deal Value Over $2.1 Billion

Collaboration to Advance Targets and Therapeutic Candidates

SAN FRANCISCO--(BUSINESS WIRE)-- insitro


 For more information on insitro, please visit the company’s website at www.insitro.com. 


 View source version on businesswire.com: https://www.businesswire.com/news/home/20201028005276/en/ 

 

Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders

 Oct. 28, 2020 7:26 AM ET|About: Bristol-Myers Squibb Company (BMY)|By: Vandana Singh, SA News Editor 

https://seekingalpha.com/news/3627107-insitro-inks-five-year-pact-bristol-myers-for-neurodegenerative-disorders


https://seekingalpha.com/symbol/BMY


Leading the way to better medicines through predictive models, created by machine learning and biology at scale.

Jazz Pharmaceuticals acquires SpringWorks Therapeutics' FAAH inhibitor program

Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New G

Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New G

 

Jazz Pharmaceuticals Acquires SpringWorks Therapeutics' FAAH Inhibitor Program

Mon October 26, 2020 7:30 AM|PR Newswire|About: JAZZ, SWTX

Strategically Expands Jazz's Mid-Stage Neuroscience Pipeline into a New Disease Area and Further Optimizes SpringWorks' Strategic Focus on Targeted Oncology

Jazz to Make Upfront Payment of $35 Million to SpringWorks with Potential Milestone Payments of Up to $375 Million

PR Newswire

DUBLIN and STAMFORD, Conn., Oct. 26, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) and SpringWorks Therapeutics, Inc. (SWTX)


 For more information, please visit www.jazzpharmaceuticals.com  


 For more information, visit www.springworkstx.com  


 View original content to download multimedia:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-acquires-springworks-therapeutics-faah-inhibitor-program-301159303.html 


https://www.springworkstx.com/pipeline/


https://www.jazzpharma.com/science/pipeline/


https://seekingalpha.com/symbol/JAZZ


https://seekingalpha.com/symbol/SWTX


 

October 26, 2020

Jazz Pharmaceuticals Acquires SpringWorks Therapeutics’ FAAH Inhibitor Program

PDF Version



Pipeline SpringWorks Therapeutics is advancing a diversified pipeline of targeted oncology programs being evaluated as standalone and combination therapies. Our development programs include two potentially registrational clinical trials in rare tumor types as well as several other programs addressing highly prevalent, genetically defined cancers. Our team is working with urgency on behalf of the underserved patients living with these devastating illnesses.

Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New G

Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New G

Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New G

 

Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy

Fri October 23, 2020 8:00 AM|GlobeNewswire|About: RARE, SLDB

-Collaboration combines Solid’s differentiated microdystrophin construct and Ultragenyx’s HeLa PCL manufacturing platform for use with AAV8 and variants-

-Solid receives $40 million upfront via equity investment at a premium; up to $255 million in milestones plus royalty payments-

-Solid retains exclusive rights to all other uses of its microdystrophins, including its existing SGT-001 program-

NOVATO, Calif. and CAMBRIDGE, Mass., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (RARE)


 For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com. 


 For more information, please visit www.solidbio.com. 


https://seekingalpha.com/symbol/RARE


https://www.ultragenyx.com/pipeline/


 Toggle Summary Oct 23, 2020Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy 

Ultragenyx is a biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no typically no approved therapies treating the underlying disease.

Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New G

Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines

 

Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwan

Mon October 12, 2020 4:05 PM|GlobeNewswire|About: ATNX

BUFFALO, N.Y., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Axis Therapeutics Limited, a joint venture between Athenex, Inc. (ATNX) and Xiangxue Life Sciences Limited (“XLifeSc”), focused on the research, development, and commercialization of T cell immunotherapy, today announced that it has entered into a research collaboration with PharmaEssentia Corporation (Taipei Exchange: 6446). 


 For more information, please visit: www.axistherapeutics.com. 


 For more information, please visit www.pharmaessentia.com . 


 For more information about XPH, visit www.xphcn.com. 


 For more information, please visit www.athenex.com. 


https://seekingalpha.com/symbol/ATNX


 

Axis Therapeutics inks research pact with PharmaEssentia for cancer T-cell therapy

Oct. 12, 2020 4:20 PM ET|About: Athenex, Inc. (ATNX)|By: Vandana Singh, SA News Editor  

https://seekingalpha.com/news/3621525-axis-therapeutics-inks-research-pact-pharmaessentia-for-cancer-t-cell-therapy



Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines

Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines

Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines

 

Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines for Neurological Diseases, Including Amyotrophic Lateral Sclerosis

Tue October 6, 2020 10:00 AM|Business Wire|About: BIIB

Committed to expanding treatment for underserved genetic conditions, Scribe and Biogen to collaborate on the development of novel genetic medicines for neurodegeneration

ALAMEDA, Calif.--(BUSINESS WIRE)-- Scribe Therapeutics Inc., the company focused on engineering the most advanced platform for CRISPR-based genetic medicine, today announced a research collaboration with Biogen Inc. (BIIB) to develop and commercialize CRISPR-based therapies that address an underlying genetic cause of Amyotrophic Lateral Sclerosis (ALS).


 To learn more about Scribe’s mission to rewrite the story of disease, visit www.scribetx.com 


 

View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005506/en/


https://www.scribetx.com/


https://seekingalpha.com/symbol/BIIB

Scribe is building and applying a suite of CRISPR technologies designed for therapeutic use into a single continually evolving and expanding genetic modification platform. We are rapidly generating hundreds of synthetic CRISPR molecules and novel technologies every month and folding the best into a fully integrated set of genome editing modalities.

Innovent Bio's expanded collaboration with Lilly for Tyvyt now effective

Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines

Innovent Bio's expanded collaboration with Lilly for Tyvyt now effective

 

Innovent Announces the Effectiveness of the Expanded Global Collaboration with Lilly on TYVYT® (sintilimab injection) Following the Expiration of HSR Act Waiting Period

Tue October 6, 2020 8:00 PM|PR Newswire|About: IVBIY

SAN FRANCISCO and SUZHOU, China, Oct. 6, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (IVBIY) ("Innovent") (HKEX: 01801)


 For more information, please visit: www.innoventbio.com. 


 View original content:http://www.prnewswire.com/news-releases/innovent-announces-the-effectiveness-of-the-expanded-global-collaboration-with-lilly-on-tyvyt-sintilimab-injection-following-the-expiration-of-hsr-act-waiting-period-301146892.html 


 

Innovent Bio's expanded collaboration with Lilly for Tyvyt now effective

Oct. 7, 2020 12:38 AM ET|About: Innovent Biologics, Inc. (IVBIY)|By: Mamta Mayani, SA News Editor  

https://seekingalpha.com/news/3620325-innovent-bios-expanded-collaboration-lilly-for-tyvyt-now-effective


http://innoventbio.com/en/#/product/products


https://seekingalpha.com/symbol/LLY

PRODUCT CENTER Innovent has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 4 products, TYVYT® (sintilimab injection), BYVASDA® (bevacizumab injection), SULINNO® (adalimumab injection), HALPRYZA® (rituximab injection) officially approved for marketing in China, 4 assets in Phase III or pivotal clinical trials, and additional 15 molecules in or close to clinical trials. TYVYT® has been the only PD-1 inhibitor included in the NRDL since 2019. Sintilimab, an innovative biological drug that independently developed by Innovent Biologics, Inc. (Suzhou), is a fully humanized IgG4 monoclonal antibody. It can specifically bind to PD-1 expressed on the surface of T cells to block this immune escape pathway, reactivate T cells, and release cytokines to kill tumor cells.Sintilimab, an innovative biological drug that independently developed by Innovent Biologics, Inc. (Suzhou), is a fully humanized IgG4 monoclonal antibody. It can specifically bind to PD-1 expressed on the surface of T cells to block this immune escape pathway, reactivate T cells, and release cytokines to kill tumor cells.

Takeda and Arrowhead Pharmaceuticals team up in rare liver disease

Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines

Innovent Bio's expanded collaboration with Lilly for Tyvyt now effective

 

Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease

Thu October 8, 2020 7:30 AM|Business Wire|About: ARWR, TAK

−        Potential first-in-class therapy designed to treat the underlying cause of liver disease associated with AATD

−        Arrowhead is eligible to receive up to $1.04B including an upfront payment of $300M and potential development, regulatory and commercial milestones up to $740M

−        Investigational medicine ARO-AAT to be co-developed and co-commercialized in the United States by Takeda (TKPHF) and Arrowhead under a 50/50 profit-sharing structure

−        Takeda receives exclusive license to commercialize ARO-AAT outside the U.S.

−        Arrowhead will hold a conference call and webcast today, Oct. 8, at 8:30 a.m. ET

OSAKA, Japan & PASADENA, Calif.--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (ARWR) 


 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005340/en/


 For more information, visit https://www.takeda.com. 

https://www.takeda.com/investors/


 For more information, please visit www.arrowheadpharma.com 


https://seekingalpha.com/symbol/ARWR

 

Pipeline

Novel Drugs to
Treat Intractable Diseases

https://arrowheadpharma.com/pipeline/

 

Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease

October 8, 2020 Osaka, JAPAN, and Pasadena, CALIF.

  • Potential first-in-class therapy designed to treat the underlying cause of liver disease associated with AATD
  • Arrowhead is eligible to receive up to $1.04B including an upfront payment of $300M and potential development, regulatory and commercial milestones up to $740M
  • Investigational medicine ARO-AAT to be co-developed and co-commercialized in the United States by Takeda and Arrowhead under a 50/50 profit-sharing structure
  • Takeda receives exclusive license to commercialize ARO-AAT outside the U.S.
  • Arrowhead will hold a conference call and webcast today, Oct. 8, at 8:30 a.m. ET

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) 

https://www.takeda.com/newsroom/newsreleases/2020/takeda-and-arrowhead-collaborate-to-co-develop-and-co-commercialize-aro-aat-foralpha-1-antitrypsin-associated-liver-disease/

Pipeline Novel Drugs to Treat Intractable Diseases

BiotechVortex™

Bristol Myers Squibb to acquire Myokardia for $13.1B in cash

CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China

CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China

 

Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash

Mon October 5, 2020 6:30 AM|Business Wire|About: BMY, MYOK

Mavacamten Is a Potential First-in-Class Medicine with Compelling Data in the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Mavacamten Will Be a Medium- and Long-Term Growth Driver Presenting a Significant Commercial Opportunity upon Approval

Promising Portfolio of Pipeline Candidates Strengthens and Extends Bristol Myers Squibb’s Leading Cardiovascular Franchise

Expected to be Accretive to Non-GAAP Earnings Starting in 2023

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (MYOK)


 For more information about Bristol Myers Squibb, visit us at BMS.com  


  www.myokardia.com 


 

View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005381/en/


 

Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash

10/05/2020CATEGORY: 

  • Corporate/Financial News

Mavacamten Is a Potential First-in-Class Medicine with Compelling Data in the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Mavacamten Will Be a Medium- and Long-Term Growth Driver Presenting a Significant Commercial Opportunity upon Approval

Promising Portfolio of Pipeline Candidates Strengthens and Extends Bristol Myers Squibb’s Leading Cardiovascular Franchise

Expected to be Accretive to Non-GAAP Earnings Starting in 2023

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire MyoKardia for $13.1 billion, or $225.00 per share in cash. The transaction was unanimously approved by both the Bristol Myers Squibb and MyoKardia Boards of Directors and is anticipated to close during the fourth quarter of 2020.

https://news.bms.com/news/corporate-financial/2020/Bristol-Myers-Squibb-to-Acquire-MyoKardia-for-13.1-Billion-in-Cash/default.aspx


https://seekingalpha.com/symbol/MYOK


https://seekingalpha.com/symbol/BMY



MyoKardia

CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China

CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China

CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China

 

CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China

Tue September 29, 2020 11:22 PM|Business Wire|About: LGND, PFE

  • Pfizer (PFE) to invest $200 million in CStone shares and license CStone’s late-stage oncology asset sugemalimab (CS1001, PD-L1 antibody) in mainland China
  • CStone to receive up to $280 million in milestone payments for sugemalimab, and additional royalties
  • CStone and Pfizer to develop and commercialize additional late-stage oncology therapies in Greater China

SUZHOU, China--(BUSINESS WIRE)-- CStone Pharmaceuticals (CSPHF) (“CStone”, HKEX: 2616)] and Pfizer Investment Co. Ltd. ("Pfizer Investment") and Pfizer Corporation Hong Kong Limited ("Pfizer Hong Kong") (both of which are subsidiaries of Pfizer Inc.)


 For more information about CStone, please visit: www.cstonepharma.com. 


http://www.cstonepharma.com/en/


 For more information, please visit www.pfizer.com.cn. 


 View source version on businesswire.com: https://www.businesswire.com/news/home/20200929006175/en/ 


https://seekingalpha.com/symbol/PFE


https://seekingalpha.com/symbol/CSPHF


 CSTONE PHARMACEUTICALS - B (2616) 

https://www.hkex.com.hk/Market-Data/Securities-Prices/Equities/Equities-Quote?sym=2616&sc_lang=en



CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China Times:2020.09.30 Author:CStone Pfizer to invest $200 million in CStone shares and license CStone’s late-stage oncology asset sugemalimab (CS1001, PD-L1 antibody) in mainland China CStone to receive up to $280 million in milestone payments for sugemalimab, and additional royalties CStone and Pfizer to develop and commercialize additional late-stage oncology therapies in Greater China (SUZHOU, China, Sept 30, 2020) CStone Pharmaceuticals (“CStone”, HKEX: 2616)] and Pfizer Investment Co. Ltd. ("Pfizer Investment") and Pfizer Corporation Hong Kong Limited ("Pfizer Hong Kong") (both of which are subsidiaries of Pfizer Inc. (NYSE: PFE)) announced today the formation of a strategic collaboration that encompasses a $200 million equity investment by Pfizer Hong Kong in CStone, collaboration between CStone and Pfizer Investment for the development and commercialization of CStone’s sugemalimab (CS1001, PD-L1 antibody) in mainland China, and a framework between CStone and Pfizer Investment to bring additional oncology assets to the Greater China market.

Roche doubles down on promising inflammation field with Inflazome buy

CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China

Roche doubles down on promising inflammation field with Inflazome buy

 

Inflazome Announces Acquisition by Roche

Mon September 21, 2020 2:00 AM|Business Wire|About: RHHBY

  • Inflazome is a pioneering inflammasome company developing orally available NLRP3 inflammasome inhibitors to address clinical unmet needs across a wide variety of inflammatory diseases
  • Acquisition of Inflazome gives Roche (RHHBY) full rights to the Inflazome portfolio
  • Activation of the NLRP3 inflammasome in the body is implicated in many diseases caused by chronic, uncontrolled inflammation
  • Inflazome shareholders received €380 million upfront, and are eligible to receive additional milestone payments

DUBLIN & CAMBRIDGE, England--(BUSINESS WIRE)


 View source version on businesswire.com: https://www.businesswire.com/news/home/20200920005066/en/ 


https://www.cell.com/fulltext/S0092-8674%2810%2900075-9


https://seekingalpha.com/symbol/RHHBY


 

Roche doubles down on promising inflammation field with Inflazome buy

Sep. 26, 2020 12:30 AM ET|About: Roche Holding AG (RHHBY)|By: Douglas W. House, SA News Editor  

https://seekingalpha.com/news/3616633-roche-doubles-down-on-promising-inflammation-field-inflazome-buy



Biotech Roche pays €380M for NLRP3 biotech Inflazome, claiming a leading position in hot field by Nick Paul Taylor | Sep 21, 2020 5:38am

Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement

Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development

Roche doubles down on promising inflammation field with Inflazome buy

 

Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease

Wed September 23, 2020 2:00 AM|Business Wire|About: PFE

PARIS & NEW YORK--(BUSINESS WIRE)-- Vivet Therapeutics 


 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200922005790/en/ 


 Please visit us on www.vivet-therapeutics.com  


 

PFIZER SECURES EXCLUSIVE OPTION TO ACQUIRE GENE THERAPY COMPANY VIVET THERAPEUTICS

Pfizer and Vivet to collaborate on development of potential breakthrough therapy for Wilson disease

Pfizer acquires 15% ownership stake in Vivet

Paris, France and New York, US, March 20, 2019 – Vivet Therapeutics (“Vivet”),

https://www.vivet-therapeutics.com/en/news-events/latest/pfizer-secures-exclusive-option-to-acquire-gene-therapy-company-vivet-therapeutics


https://seekingalpha.com/symbol/PFE



Product Pipeline

Pepinemab in Combination with KEYTRUDA

Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development

Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development


Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Thu September 17, 2020 8:00 AM|GlobeNewswire|About: VCNX

ROCHESTER, N.Y., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX)


http://www.vaccinex.com/



Vaccinex partners with Merck in cancer

Sep. 17, 2020 8:31 AM ET|About: Vaccinex, Inc. (VCNX)|By: Mamta Mayani, SA News Editor  .com/news/3614927-vaccinex-partners-merck-in-cancer

https://seekingalpha.com/news/3614927-vaccinex-partners-merck-in-cancer


http://www.vaccinex.com/pipeline/pepinemab-immuno-oncology/


https://seekingalpha.com/symbol/VCNX



 Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

ROCHESTER, N.Y., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX)

http://ir.vaccinex.com/news-releases/news-release-details/vaccinex-announces-clinical-collaboration-merck-evaluate




Pepinemab Immuno-Oncology First in class, anti-SEMA4D immunotherapy for cancer.

Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development

Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development

Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development

 

Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development

Thu September 17, 2020 8:30 AM|Accesswire|About: DYAI

LIANYUNGANG, CHINA and JUPITER, FL / ACCESSWIRE / September 17, 2020 / Dyadic International, Inc. (DYAI) ("Dyadic" or the "Company") (NASDAQ:DYAI)


 Please visit Dyadic's website at http://www.dyadic.com for additional information 


 please visit http://www.hrs.com.cn/index.html. 


http://www.hrs.com.cn/index.html


https://www.hengruitx.com/


 

Dyadic teams up with Jiangsu Hengrui for biologic drug development

Sep. 17, 2020 9:05 AM ET|About: Dyadic International, Inc. (DYAI)|By: Mamta Mayani, SA News Editor  

https://seekingalpha.com/news/3614955-dyadic-teams-up-jiangsu-hengrui-for-biologic-drug-development


  http://www.dyadic.com/. 


https://seekingalpha.com/symbol/DYAI


https://www.hengruitx.com/rd.html#Htipipe

HTI U.S. / GLOBAL CLINICAL STUDIES

BiotechVortex™

Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies

Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies

Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies